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ABSTRACT OF DISSERTATION
PPAP2B EXPRESSION LIMITS THE DEVELOPMENT OF LESION
FORMATION IN MURINE MODELS OF ATHEROSCLEROSIS

Coronary artery disease (CAD) is the leading cause of death in both men and women
worldwide and is defined as a narrowing of the coronary arteries due to accumulation of
atherosclerotic plaques. Genome-wide association studies have identified risk loci within
the gene PPAP2B that confers increased risk of developing CAD. Evidence suggests
these aforementioned SNPs are regulating PPAP2B expression in a cis-manner through
the interruption of transcription factor binding sites. PPAP2B encodes the lipid phosphate
phosphatase 3 enzyme that plays a key role in degrading bioactive lysophosphatidic acid
(LPA). LPA has a plethora of effects on vascular tissue and is implicated in increasing
inflammation and exacerbating the development of atherosclerotic lesions in mice.
Interestingly, PPAP2B expression is increased in murine models of atherosclerosis and
both global and smooth muscle cell-specific deletion increases the development of lesions
compared to control mice. LPP3-deficient mice with increased atherosclerosis show
significant increases in LPA accumulation in their proximal aorta as well as increased
expression of inflammatory markers and positive staining for leukocyte marker CD68.
Globally deficient mice also show substantial increases in ICAM-1 staining in their aortic
root lesions relative to controls. Preliminary evidence also suggests that total LPA content,
and specifically unsaturated LPA species, increase in the atherogenic LDL-C fractions of
plasma in hyperlipidemic mice prone to developing atherosclerosis. Taken together, these
data suggest that as CAD develops, LPA accumulates in atherosclerotic plaques, and the
intrinsic mechanism of defense is to upregulate LPP3 through transcription factormediated effects on PPAP2B; however, individuals harboring the previously mentioned
risk alleles are unable to increase PPAP2B expression and thus experience unchecked
inflammation and exacerbated development of atherosclerosis.
KEYWORDS: Lipid phosphate phosphatase 3 (LPP3), Lysophosphatidic acid (LPA),
genome-wide association studies (GWAS), inflammation, low density lipoproteins (LDLC), coronary artery disease (CAD)
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Chapter 1: Introduction
Since 1921 cardiovascular disease (CVD) is the leading cause of death of both men and
women worldwide. From 2003 to 2013 death rates attributable to CVD declined 28.8%
with the actual number of deaths per year dropping 11.7% in the United States[1]. These
declines in death rates and total death toll are a display of progress, but it is important to
note that in 2013 30.8% of all 2,596,993 deaths in the United States are still attributed to
CVD [2]. Needless to say, in spite of declining rates of disease, CVD remains a significant
burden on the United States and accounts for an estimated $316.6 billion burden annually
[2]. With an estimated 15.5 million Americans over the age of 20 that suffer from CAD [3]
there has been a focus on understanding not only the vascular pathophysiology, but also
the factors that predispose an individual to an increased risk of disease. Bioactive lipids
have taken a spotlight in the regulation and modulation of vascular pathophysiology. This
chapter will discuss one such bioactive lipid, Lysophosphatidic acid (LPA), and its role in
regulating vascular pathology. LPA, and its regulators autotaxin (ATX) and lipid phosphate
phosphatase 3 (LPP3), play integral roles in components of vascular physiology and
pathophysiology that are key steps in the development and progression of CAD. This
chapter will discuss in detail the burden and specific mechanisms of CAD pathology and
break down tissue-specific contributions to disease progression. Identifying risk factors
contributing to CAD is essential to its prevention and treatment; as such, advances in
genome-wide sequencing to identify genomic loci conferring risk of disease has become
a rapidly developing field. Genome-wide association studies (GWAS) will be described in
addition to a specific locus in the gene PPAP2B which confers increased risk of disease
[4]. PPAP2B encodes the LPA-degrading protein LPP3 which has been implicated in both
embryonic development and vascular disease. LPP3 structure and function will also be
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described in detail. The aim herein is to illustrate a role for LPA and its regulators in the
pathophysiology of CAD.

Lysophosphatidic Acid1
LPA is a bioactive lysophospholipid composed of a phosphate molecule bound to a
glycerol backbone, which bears a variable length fatty acid chain (Figure 1.1). LPA is found
in all eukaryotic tissues in low concentrations and its activity is dependent on its binding
to one of six known extracellular G protein-coupled receptors (GPCRs) termed LPA
receptor 1 – 6 (LPA1 – LPA6) which are differentially expressed throughout various tissues
and cells [5-9]. Any given LPA receptor is capable of activating at least 2 of the 4 known
g-protein complexes eliciting a variety of cell responses ranging from cytoskeletal
rearrangement, migration, proliferation, survival and mild platelet activation [10-15]. In fact,
the lysophospholipid was first identified in 1963 as a regulator of blood pressure mediating
effects through smooth muscle cell function [16, 17]. LPA can be generated via two
pathways: 1) lysophospholipase D activity of ATX hydrolysis of lysophosphotidylcholine
and 2) phospholipase A2-mediated deacylation of phosphatidic acid leads to LPA
production [18]. Pathways for production will be described in section “LPA Biosynthesis”.
Degradation of LPA can occur through the actions of a family of membrane-bound proteins
termed lipid phosphate phosphatases (LPPs), which are discussed in more detail in
section “PPAP2B Encodes Lipid Phosphate Phosphatase 3”.

1

Portions of this section were taken from Mueller et al. [15]. Some additions and

modifications to the text and figures have been made for clarity of information.
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LPA Receptor Signaling
The receptors for LPA are widely distributed on blood and vascular cells. In preclinical
animal models, targeting the LPA receptors genetically and pharmacologically suggest
that they may contribute to vascular injury and inflammatory responses, as well as
endothelial barrier function and vascular stability. Single and multiple deletions of LPA
receptors in mice produce differing vascular phenotypes. Deficiency of Lpar1, which
results in 50% neonatal lethality, gives rise to the development of spontaneous frontal lobe
hematomas [19]. This suggests a role for LPA1 in stabilization of vessels, as no defect in
hemostasis has been observed in these animals. In experimental arterial injury models,
LPA1 regulates the development of intimal hyperplasia, a complex response involving
inflammation and smooth muscle cell proliferation and migration. LPA1 may influence the
vascular remodeling response via the Gα12/Gα13 pathway that couples to RhoGEF to
activate RhoA, given the similarities in development on intimal hyperplasia after injury in
the Lpar1-/- mice [10] and those lacking the Gα12/Gα13 and Rho pathways [20] in smooth
muscle cells. The lack of LPA1 disrupts the endothelial barrier and results in increased
vascular permeability in response to inflammatory stimuli in the lung [21] and the skin [22].
Conversely, LPA1 antagonists prevent inflammation in response to peritoneal injection of
lipopolysaccharide [23]. Whether either a defect in smooth muscle or endothelial cell
function accounts for the bleeding observed in the Lpar1-/- mice remains unknown.
Knockout of both Lpa1 and Lpa2 increases the incidence of prefrontal hematomas [24],
impairs the response to vascular injury [10], and results in the development of pulmonary
hypertension with age [25]; the latter phenotype is not observed in mice with deficiency of
either of the receptors alone. Together, these results suggest some redundancy or overlap
between the 2 receptor systems. Likewise, LPA1 and LPA3 antagonists, Ki16425, reduce
arterial remodeling elicited by denudation injury [11] in mice, perhaps due to attenuated
signaling through both Gα12/Gα13 and Gq/G11 signaling pathways, which appear to

3

regulate vascular remodeling antagonistically. Lpar4-deficient mice display a genetic
background-dependent defect in formation of vasculature. On the C57Bl/6 background,
the mice develop hemorrhage and edema due to a maturation defect from lack of smooth
muscle cell and pericyte recruitment to vessels [26]. Additionally, LPA signaling through
RAGE may also affect SMC function [27]. As described in more detail below, studies in
zebrafish also support a role for several of the canonical LPA receptors in blood vessel
formation
LPA Biosynthesis
LPA is present in many biologic fluids, including plasma, ascites, and bronchoalveolar
lavage fluid. In the circulation, LPA turns over rapidly [28] and therefore must be
maintained by constant production. Certain conditions, such as acute coronary syndromes
[29, 30] and chronic liver disease [31] are associated with higher levels of plasma LPA.
Whether this is due to increased production or reduced clearance or both is currently not
known. As mentioned before there are several pathways that can generate LPA. The
secreted lysophospholipase D ATX generates extracellular LPA by hydrolysis of
lysophosphatidylcholine

(LPC)

[32-34].

ATX

is

an

ecto-nucleotide

pyrophosphatase/phospho-diesterase family member (encoded by ENPP2 in humans and
Enpp2 in mice) that is synthesized as a pre-proenzyme and undergoes sequential signal
peptide removal and proprotein convertase cleavage before being secreted from cells. Of
five functional isoforms (ATXα, ATXβ, ATXγ, ATXδ, and ATXε) generated through
alternative splicing, ATXβ is the most abundant and appears to account for most of the
lysophospholipase D activity in plasma. The cellular source(s) of plasma ATX are
incompletely understood, however, adipocytes likely secrete a substantial portion [35].
ATX is also stored in platelets and released during their activation [34, 36]. Circulating
ATX is rapidly taken up by scavenger receptors of liver sinusoidal endothelial cells, the
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same class of receptors capable of clearing formylated and maleyted BSA, and then
degraded in the liver [37]. Thus, much like hormones, including insulin, ATX is largely
removed from the circulation during first passage through the liver. While ATX is normally
a major source of plasma LPA levels [28, 38], other minor pathways may contribute to
increases in LPA in certain situations, such as in the setting of acute myocardial infarction
[29, 30, 39].
Autotaxin’s Role in Vascular Development
Studies of organisms that lack or express catalytically-inactive ATX have shed light on its
role, and by inference, the role of LPA signaling, in vascular biology. ATX expression is
required for normal vascular development in mice. Enpp2-deficient mice [40, 41] die
between embryonic days 9.5–10.5 with blood vessel formation defects in the yolk sac and
embryo. In the absence of ATX, initial blood vessel formation appears normal, but vessels
fail to mature, suggesting that ATX is critical for extension and stabilization of blood
vessels but perhaps not for the initial endothelial cell differentiation and migration. The
phenotype of Enpp2-/- mice resembles that observed in Gα13 knockout embryos, which
would be consistent with ATX-generated LPA signaling through Gα13-coupled receptors.
To date, no single or multiple LPA receptor knock-out mice have fully recapitulated the
phenotype observed in embryos lacking ATX or Gα13. However, mice expressing a
functionally inactive ATX (T210A) also die embryonically [42], indicating that the catalytic
activity of ATX, and likely LPA synthesis, is essential for vascular development. Enpp2heterozygous mice are viable and express half of normal levels of ATX and LPA. However,
they are hyper-responsive to hypoxia-induced vasoconstriction and remodeling, and
prone to develop pulmonary hypertension [25]. Knockdown of ATX in zebrafish embryos
by morpholino antisense oligonucleotides also causes aberrant vascular connections with
normal initial sprouting; interestingly, while knockdown of each single LPA receptor by
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morpholino antisense oligonucleotides show little phenotype, attenuating LPA1 and LPA4
signaling recapitulated the ATX knockdown vascular defects [43].
As described above, ATX and LPA-signaling contributes to the development of embryonic
vasculature in multiple species and LPA-receptor signaling affects vEC- and SMC-function
in mature mice. LPA is also implicated in the development and progression of CAD. Levels
of vessel-associated LPA increase during progression of atherosclerosis [44, 45] and are
substantially higher in advanced lesions [46]. Cholesterol feeding influences levels and
distribution of plasma LPA in rabbits [47]. Additionally, feeding mice a chow diet
supplemented with unsaturated LPA mimics the inflammatory effects of Western diets
[48]. LPA that is generated during atherosclerosis may have pro-atherosclerotic, proinflammatory, and pro-thrombotic effects [4].

Cardiovascular Disease Burden2

Coronary artery disease (CAD) is due to a narrowing of the heart’s blood vessels
(stenosis) on account of the buildup of atherosclerotic plaques. Based on data from the
National Health and Nutrition Examination Survey (NHANES), in 2013, CAD accounted
for 1 out of every 7 deaths. Each year roughly 660,000 Americans suffer from a new
myocardial infarction (MI), better known as a heart attack, and 305,000 have a recurrent
attack. It is estimated that 15.5 million Americans over the age of 20 suffer from this
disease with a prevalence of 7.6% and 5.0% of adult men and women respectively. The
high prevalence of this disease is coupled with a high mortality rate that makes this

Data presented in this section are from the AHA’s annual publication on Heart Disease and
Stroke Statistics [2].
2
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disease such an impactful epidemic throughout the world. In fact, 34% of individuals who
experience a coronary event -- defined as a MI, ischemic heart failure, or unstable angina
-- will die of it. Data from large trials including the Framingham Heart Study,
Atherosclerosis Risk in Communities Study, and several others indicate that within 1 year
following a first MI 18% of men and 23% of women over the age of 45 will die. Within 5
years those numbers increase to 36% in men and 47% in women. These high rates of
prevalence and subsequent consequences in mortality associated with CAD make it
imperative that efforts in medical research are dedicated to understanding, predicting and
treating not just CAD but CVD as a whole.

Risk Factors of Cardiovascular Disease
Framingham Heart Study Defines Classic Risk Factors
Classical risk factors for the development of CVD were first discovered through the
Framingham Heart Study in 1948. These classical risk factors include both modifiable
lifestyle behaviors and non-modifiable risk factors. Modifiable risk factors include
dyslipidemia, hypertension, physical inactivity, type 2 diabetes, alcohol consumption and
smoking [49, 50] whereas some of the non-modifiable risk factors include a family history
of disease as well as aging itself. It is worth mentioning that in the United States there has
been a significant decline in the incidence of modifiable risk factors such as smoking in
adults which is currently at 16.9% (down from 24.1% in 1998) as well as certain aspects
of nutritional quality, specifically the prevalence of ideal levels of diet which increased from
0.7% to 1.5% in adults from 2004 to 2012 [3]. This is good news, but smoking is still
attributed to at least one third of all CAD related deaths and poor nutrition was the leading
risk factor in 2010 for death and disability with 678,000 annual deaths attributable to all
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causes [3]. Unfortunately, the prevalence of other modifiable risk factors has increased
such as the death rate attributable to hypertension which increased 8.2% from 2003 to
2013 and the prevalence of type 2 diabetes in children and adolescents has increased
30.5% from 2001 to 2009 [3]. Lastly, based on data from 2009 and 2012, greater than
100 million adults in the United States over 20 years of age have total cholesterol over
200 mg/dL; and roughly 31 million have total cholesterol levels over 240 mg/dL [3].

Cardiovascular Disease Pathogenesis

Classifying the Progression of CAD
CVD is representative of several subcategories of disease such as CAD or ischemic heart
disease, stroke, peripheral artery disease, heart failure and others. This section will focus
on the pathogenesis of CAD which is the more deadly and the more costly subcategory of
CVD. In 1994 and 1995, Herbert Stary led the AHA’s Committee on Vascular Lesion along
with the Council on Ateriosclerosis and created a histology based scoring system to define
atherosclerotic plaque progression which has become known as the Stary scoring system
[51, 52].
Naïve healthy arteries consist of a tunica intima layer composed of a single endothelial
cell layer separating the lumen of the blood vessel from an underlying subendothelial
matrix and a layer of internal elastic lamina. The tunica media surrounds the tunica intima
and consists of layers of vascular smooth muscle cells and internal elastic lamina that act
in consortium to both resist the stretch from the blood pressure as well as regulate vessel
diameter. The outermost layer is the tunica adventitia which is primarily connective tissue
and supportive structures such as blood vessels, known as the vasa vasorum, and nerves.
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Type I plaques begin to develop during the first decade of life and are characterized by
the deposition of low density lipoprotein cholesterol (LDL-C), which becomes oxidized over
time, and an accumulation of foam cells in the subintimal space of coronary arteries [52].
Foam cells are lipid laden macrophage-like cells that develop as circulating monocytes,
infiltrate the intimal layer through activated vascular endothelial cells (vECs), differentiate
into macrophages and endocytose oxidized LDL-C (oxLDL) particles. A key step in type I
plaque progression is the activation of vECs which tends to occur primarily in areas of
turbulent or disturbed blood flow, typically around a curvature or bifurcation in the artery
[53, 54]. The mechanical stress induced by the turbulent flow on vECs results in the
recruitment of leukocyte adhesion molecules such as ICAM-1 and VCAM-1 on their
luminal surface [54, 55]. It is through these adhesion molecules that circulating monocytes
are able to “stick” to the vEC layer and infiltrate the subintimal space via diapedesis, a
process that will be expanded upon later in this chapter. This process of vEC activation,
monocyte infiltration and uptake of oxLDL via macrophages will continue to occur
throughout the development of CAD and plays a primary role in the continued
development of atherosclerotic plaques.
The appearance of yellow fatty streaks on a vessel wall signifies the next state in the
development of CAD [51, 52]. These fatty streaks are representative of a large
accumulation of foam cells that are swollen with endocytosed oxLDL. Only one feature
distinguishes Type II from Type III plaques and that is the generation of an extracellular
lipid pool in addition to the fatty streaks [51, 52].
Type II and III plaques are prone to give rise to Type IV plaques or atheromas. Atheromas
are known for their well-defined lipid core [51] that develops as outward remodeling of the
vessel progresses. In coronary vessels, a distance of ~200µm from the lumen is far
enough to generate an ischemic environment subsequently leading to apoptosis and the
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beginnings of a necrotic core [56]. Along with creating an ischemic environment, this
extracellular pool of lipids accumulates insoluble crystals of cholesterol, which are toxic,
and trigger nearby cells to undergo apoptosis [56, 57]. In a healthy physiological state,
macrophages participate in efferocytosis, which is classified as a process in which
apoptotic cells are “cleaned up” or cleared away in the tissue. However, the foam cells
present in atherosclerotic tissue are not classical macrophages and are unable to carry
out efferocytosis properly [58]; consequently, dead cell fragments and the artifacts of
apoptotic cells remain in the tissue contributing to increased inflammation and a
prothrombotic “stew” [56, 59]. High concentrations of the highly thrombotic protein tissue
factor (TF) contribute significantly to the ability of the necrotic core to induce thrombosis if
exposed to the circulation [60]. At this stage in CAD, there is still little stenosis of the
coronary artery but there is still risk of artery occlusion due to thrombosis should the
contents of the plaque leak into the bloodstream via rupture.
True stenosis occurs in Type V atherosclerotic plaques. A Type V plaque is characterized
by the neointimal accumulation of migrated dedifferentiated vascular smooth muscle cells
(vSMCs) which generate a tough fibrous cap between the fatty necrotic core and the lumen
of the blood vessel [51]. The continued proliferation of vSMCs in the neointima in concert
with increased deposition of extracellular matrix leads to the growth of the plaque into the
lumen of the blood vessel which can, over time, lead to reduced blood flow or even
occlusion of the artery [56, 59]. Interestingly, the generation of a fibrous cap over the
atherosclerotic plaques makes the diseased tissue less likely to rupture. Type V plaques
are susceptible to a plethora of developmental changes that lead to the most clinically
relevant classification of plaques, Type VI plaques.
Type VI plaques experience intraplaque hemorrhage, fission, intimal denudation and
expansive calcium deposition all of which leave the atheroma susceptible to rupture and
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subsequent thrombogenesis and MI [51, 52]. Intraplaque hemorrhage occurs through
rupture of leaky neovessels that have grown into the plaque from the vasa vasorum and
sharply increase inflammation through the lysis of red blood cells, which contributes
plasma membrane cholesterol to the necrotic core, and exposure of hemoglobin (Hb) to
the local environment [56, 61]. Hb is a highly inflammatory protein outside of the red blood
cell and contributes significantly to oxidative damage and reactive oxygen species (ROS)
[61]. Fissures are essentially tears or breaks in the endothelial or fibrous lining of the
plaque that potentially exposes the contents of the plaque to the circulation [62]. Typically
these fissures reseal as vECs proliferate and cover the exposed underlying tissue [56],
but it is particularly compromising to the integrity of the plaque as repeated fissures
increases susceptibility to rupture [63, 64]. Intimal or endothelial denudation is a process
describing the erosion of the vEC layer or fibrous cap overlying the highly pathogenic
extracellular matrix and necrotic core of the atheroma [65]. Lastly, calcium deposits occur
in the ECM, the necrotic core, and in the remnants of cells that have undergone apoptosis
[56, 59]. The pathology of calcified atheroma is unclear; however the extent of calcification
in the plaque can be used as a biomarker for advanced progression of disease [66, 67].
Many of these processes occur throughout plaque progression and are not restricted to
Type VI plaques alone; they do however occur continuously and contribute to the
development and subsequent erosion and rupture of the atheroma.
Murine Models of Atherosclerosis
Wild-type mice are resistant to the spontaneous development of atherosclerosis likely due
to their drastically different lipoprotein profile compared to humans. In humans, most of
the circulating cholesterol is found in the LDL-C whereas in mice it is in the HDL-C. Wildtype mice are also resistant to diet-induced hypercholesterolemia because, unlike
humans, they do not absorb dietary cholesterol efficiently; specifically, humans absorb
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between 53.5 and 57.2% of cholesterol when fed a high cholesterol diet [68] compared to
C57BL/6 mice that exhibit 30% absorption of cholesterol when fed a high fat/high
cholesterol diet [69]. Investigating the role of cholesterol and lipoproteins in mice began in
1992 when both Nobuya Maeda and Jan Breslow’s groups independently reported their
findings that

Apoe-/- mice spontaneously develop

hypercholesterolemia and

atherosclerosis [70, 71]. One year later Ishibashi et al. reported the generation of the Ldlr/-

mouse and the observation that a high cholesterol diet induces severe

hypercholesterolemia in these mice [72]. On regular chow diet Apoe-/- and Ldlr-/- mice
display a ≈4- to 5-fold and ≈2-fold increase in total plasma cholesterol compared to wildtype mice [72, 73]. ApoE is required for the clearance of cholesterol-rich chylomicrons and
VLDL-C particles from the plasma and mice deficient in this protein show marked
increases in plasma chylomicrons and VLDL while showing no increase in LDL-C. The
Ldlr-/- mouse is a better model for human familial hypercholesterolemia as they both exhibit
significant increases in their LDL-C; however, unlike the Apoe-/- mouse, mice deficient in
LDLr do not spontaneously develop atherosclerosis on chow diet. When placed on a high
cholesterol diet, Ldlr-/- mouse plasma cholesterol increases up to 1,500mg/dL.
These mouse models are not without their limitations. For example, the lipoprotein profile
of Apoe-/- mice is very different from the LDL-C heavy profile of humans. Additionally, while
both strains are capable of producing extensive atherosclerotic lesions, plaque rupture is
a rare occurrence and typically requires additional insults such as surgical manipulations
[74], overexpression of human proapoptotic p53 [75], or using aged mice (60+ weeks old)
[76].
Limitations aside, the Apoe-/- and Ldlr-/- mice provide a useful model of atherosclerosis in
mice and their lesions are comparable to human disease. Both Apoe-/- and Ldlr-/- mice on
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Western diet develop lesions that can be scored using the Stary System previously
described (see Table 1.1, taken from Whitman, S 2004 [77]).
Endothelial Cell Dysfunction Contributes to CAD Development
vECs compose a monolayer of cells that separates the circulating blood from the rest of
the blood vessel. They play a pivotal role in the vasculature through inhibiting platelet
activation and thus thrombogenesis through the production of both adenosine
monophosphate [78] and nitric oxide (NO) [56, 59, 79, 80]. NO and prostacyclin production
in vECs are important vasodilators that triggers SMC relaxation in response to increased
forces on the vessel wall due to high blood pressure [80-82]. Morphologically, vECs
comprise a highly organized monolayer typically aligned elongated in parallel with the
unidirectional high shear stress from laminar blood flow [59, 83, 84]. This parallel
alignment permits tight cell-cell contact maintaining both adaptive signaling [59, 85], to
inhibit proinflammatory gene expression of NF-κB through Rac-dependent ROS
production and p21 activated kinase signaling [86], and a highly regulated selective barrier
between the circulation and underlying ECM [56]. During cases of peripheral tissue
inflammation, complex leukocyte-vEC interactions permit the capture and adherence of
circulating leukocytes to the endothelium and facilitate transmigration across the vEC
monolayer [55]. These aforementioned processes are tightly regulated and maintained in
the healthy vasculature but undergo dynamic phenotypic alterations in atherosusceptible
regions experiencing disturbed blood flow and low shear stress.
Regions of the proximal aorta and the coronary arteries where inner curvature or
bifurcations of the vessel occur are known to be susceptible to atherosclerosis [53, 83].
The unidirectional high shear stress typical of laminar blood flow in atheroprotected
regions turns into turbulent blood flow with drastic changes to flow direction. Changes in
flow dynamics and direction lead to vEC activation and alter their morphology from the
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parallel elongated arrangement into a pathological “cobblestone” appearance [87]. This
altered vEC morphology coincides with dysfunction in many of the vEC processes
mentioned above. Activated vECs display enhanced inflammation and a reduction in NO
production [82], a hallmark of endothelial dysfunction, resulting in a diminished ability to
regulate vessel lumen diameter in response to increases in blood pressure as well as NOdependent inhibition of platelet activation. Both laminar and disturbed blood flow is
detected in vECs by the Rho family GTPases RhoA, Rac, and cdc42 which permits
cytoskeletal remodeling but the lack of directional flow in the atherosusceptible regions
hinders the vECs from forming tight cell-cell contact and maintaining the adaptive signaling
[88-90] mentioned previously. Compromised “cobblestone” vECs experience endothelial
barrier dysfunction, heightened proinflammatory signaling and ROS production. Enhanced
proinflammatory signaling leads to expression of the leukocyte adhesion molecules
VCAM-1 and ICAM-1 and subsequent invasion of inflammatory cells into the vessel [55],
as mentioned before, as well as increased deposition of LDL-C into the subintimal space.
Accumulated LDL-C is modified to oxLDL which then binds to CD36 and lectin-like oxLDL
receptor 1 (LOX-1) on vECs [91] leading to increased activation of ICAM-1 [92]
perpetuating the progression of monocyte invasion and plaque development. Endothelial
expression of adhesion molecules contributing to atherosclerosis is supported in murine
models of atherosclerosis in which Apoe-/- Icam1-/- double knockout mice show decreased
lesion sizes compared to Apoe-/- controls [93]. Another vEC-expressed cytokine with links
to monocyte recruitment in the context of CAD is CXCL1 by binding to its ligand CXCR2
on circulating monocytes prompting cell arrest [94].
A Role for Leukocytes and Inflammation in CAD
This section will focus on the subpopulation of leukocytes known as monocytes as they
are the predominant cell type found in atherosclerotic lesions. Monocytes make up roughly
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5 to 10% of the total leukocytes in the circulation and are comprised of two main subtypes,
GR1+/Lys6Chigh and GR1-/Lys6Clow [95]. GR1+/Lys6Chigh monocytes express CCR2, a cell
surface receptor capable of binding monocyte chemoattractant protein 1 (MCP-1) on
activated vECs, and are the primary subtype responsible for extravasation into peripheral
tissue at sites of inflammation [96]. Upon infiltration into inflamed peripheral tissue,
monocytes will differentiate into one of four known macrophage subsets. M1 macrophages
differentiate from monocytes exposed to LPS and/or IFNγ and are the subset responsible
for attacking and eliminating pathogens [97, 98]. M2 macrophages come from monocytes
treated with IL-4 or IL-13 and are implicated in tissue repair probably following the initial
M1 response in inflammation [97, 98]. A unique macrophage subset has emerged from
exposure of oxidized phospholipids, such as oxPAPC, to monocytes and bears what is
called a Mox phenotype which appears to be a blend of both M1 and M2 phenotypes [99].
Lastly, there is a subset of macrophages known as the M(Hb) macrophage which will be
discussed later in this section. Classically monocyte/macrophages are known for their role
in the innate immune response; however, there are significant maladaptive behaviors that
contribute to the development and progression of CAD.
As mentioned before, GR1+/Lys6Chigh monocytes harbor CCR2 on their plasma membrane
and are capable of binding MCP-1 expressed on activated vECs. During the early stages
of plaque development, increased expression of MCP-1, ICAM-1, VCAM-1 and
macrophage colony stimulating factor (M-CSF) [56] on the cell surface of activated vECs
is a crucial step in the recruitment of monocytes and their transmigration into the subintimal
space of blood vessels. Monocytes that differentiate into macrophages with the M1
phenotype express high levels of the scavenger receptors CD36, LOX-1, and macrophage
scavenger receptor class A (SR-A) all of which aggressively facilitate the uptake of oxLDL
into the macrophage [100, 101]. Typically free LDL-C binds LDL-C receptor (LDLR) where
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it is endocytosed in a clathrin coated pit and acidification of the vesicle liberates the LDLC from its receptor where it can act to inhibit HMGCoA reductase-dependent cholesterol
synthesis [56]. In the developing plaque however, LDL-C modified to oxLDL is
endocytosed via the aforementioned scavenger receptors and leads to unregulated
cholesterol uptake, heightened proinflammatory cytokine production, and foam cell
formation [56, 91, 102, 103]. OxLDL internalization provides specific ligands for the
nuclear hormone receptor PPARγ [104] whose activity leads to increased expression of
CD36 creating a positive feedback loop for oxLDL uptake and the exacerbation of the
foam cell phenotype [105-107]. Cd36-/- mice on an atherogenic Apoe-/- background fed
Western diet show pronounced reductions in aortic tree lesion formation (76.5%)
compared to control mice [108].
It was mentioned previously that ischemia in the atheroma leads to hypoxia-induced
apoptosis and formation of the necrotic core. Profound oxLDL uptake in foam cells can
also contribute to growth of the necrotic core as the formation of cholesterol crystals
triggers foam cell death leaving behind the toxic cholesterol crystals, oxidized lipids, and
cell remnants [58, 109]. M1 macrophage phenotypic switching to a foam cell diminishes
its ability to carry out efferocytosis, the process of cleaning up apoptotic cell fragments,
contributing to the continuous growth of the necrotic core
Lastly, as mentioned before, intraplaque hemorrhage results in the accumulation of
cholesterol and Hb in the plaque providing a source of ROS and oxidative damage. The
tissues endogenous protection against Hb-induced oxidative damage is through its
binding to haptoglobin (Hp) forming a Hb:Hp complex which can be cleared by resident
macrophages through the CD136 receptor [110]. Macrophages that uptake Hb:Hp
develop a phenotype known as M(Hb) and are unique in that they are very resistant to the
uptake of oxLDL in vitro [111]. M(Hb) macrophages are therefore considered to be
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protective in the context of atherosclerosis in that they do not develop into foam cells and
are capable of eliminating proinflammatory Hb from the atheroma.
Phenotypic Switching of Smooth Muscle Cells in Atherosclerosis
Vascular SMCs reside in the tunica media of blood vessels from arterioles up to the largest
of the arteries, the aorta, while being absent in the capillaries; structurally, SMCs are
arranged in an elongated fashion parallel to one another but perpendicular to the direction
of blood flow. The primary role of SMCs in the tunica media is to regulate the vessel lumen
diameter in response to changes in blood pressure (the myogenic mechanism), or external
stimuli from the vECs or the sympathetic nervous system, through coordinated contraction
and relaxation. Vascular SMCs are not terminally differentiated and therefore harbor
significant plasticity [56, 59]. In healthy blood vessels, SMCs maintain a “contractile”
phenotype that is characterized by low levels of proliferation and diminished capacity to
secrete ECM proteins [54]. Contractile SMC markers are smooth muscle alpha-actin
(ACTA2), smooth muscle 22α (SM22) and smooth muscle myosin heavy chain (SM-MHC)
[112]. Prostaglandin2 (PGI2) [113] and NO [114] secreted from vECs act as potent
vasodilators by acting on signaling pathways in SMCs, but these molecules also play a
significant role in maintaining the previously mentioned contractile phenotype. PGI2
stimulates adenylyl cyclase-dependent cAMP generation capable of inhibiting myosin light
chain kinase [115, 116], a kinase whose phosphorylation of the myosin light chain
stimulates SMC contraction through myosin-actin crossbridge formation, hence leading to
SMC relaxation. Aside from inhibiting crossbridge formation, PGI2 signaling decreases
intracellular Ca2+, adding to its role as a vasodilator, but also inhibits SMC proliferation
and growth [115, 116]. NO signaling leads to guanylyl cyclase-dependent cGMP
production [117], a second messenger that stimulates myosin light chain phosphatase
activity [117]. Myosin light chain phosphatase hydrolyzes the phosphate from myosin light
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chain and breaks myosin-actin crossbridges resulting in SMC relaxation. Similar to PGI2,
NO-dependent cGMP production leads to decreased intracellular Ca2+ and inhibits
proliferation and growth in SMCs [118] .
SMCs in CAD and other vascular injury models exhibit a vastly different phenotype than
the contractile SMCs described above. During atherosclerotic plaque development SMCs
dedifferentiate and migrate to the subintimal space, usually above the extracellular lipid
pool/necrotic core, and both vigorously proliferate and secrete ECM proteins such as
collagen and elastin to form a tough fibrous cap [119]. Pronounced SMC proliferation in
the subintimal region creates a condition known as neointimal hyperplasia and is
characterized best by significant increases in the intima size. vEC dysfunction increases
susceptibility to atherosclerosis and may contribute to SMC phenotypic switching from a
contractile state to a proliferative one due to loss of the NO-dependent inhibition of
proliferation in SMCs. These “proliferative” SMCs downregulate expression of their
contractile markers, ACTA2, SM22 and SM-MHC, and express macrophage markers such
as CD68 [112]. Data suggest a role for the DNA-binding protein Krüppel-like factor-4 in
binding the G/C repressor element on the promoter of SMC marker genes, leading to their
downregulation [112]. Phenotypic switching may also push SMCs towards a macrophagelike state capable of internalizing oxLDL in atherosclerotic plaques; in fact, evidence
suggests that up to 50% of oil red-O stained cells in plaques display ACTA2-positive
staining and thus may significantly contribute to the foam cell population [120]. In vitro,
vascular SMCs treated with oxidized phospholipids, such as oxPAPC, oxLDL, and
unsaturated LPA for 72 hours display phenotypic switching characterized by decreased
expression of SMC markers, upregulation of CD68 and even positive oil red-O staining
suggesting foam cell formation [121, 122].
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LPA and Atherosclerosis
LPA-mediated effects on vEC barrier function and SMC phenotypes have been reported.
Not surprisingly, LPA has also been implicated in CAD by eliciting effects through both
vEC and macrophages. Ex vivo perfusion of murine carotid artery with mildly oxidized
LDL-C (moxLDL) leads to an LPA-dependent increase in monocyte rolling and adhesion
that can be completely inhibited by the addition of the LPA1/3 antagonist Ki16425 [14]. It
appears that LPA is generated from LPC on moxLDL by ATX and blocking the enzyme
with inhibitor S32826 diminishes the rolling and adhesion of monocytes to the vessel wall
[14]. Intravenous injection (i.v.) of unsaturated 20:4 LPA, but not saturated 18:0 LPA,
increases atherosclerotic lesion formation in Apoe-/- mice fed high-fat diet for 4 weeks
displaying significantly increased macrophage Mac-2+ staining [14]. Ldlr-/- mice fed chow
diet supplemented with unsaturated LPA resulted in lesion formation similar to Western
diet fed mice, which was ameliorated by the addition of the ATX inhibitor PF8380 [123].
Evidence also supports a role for LPA in foam cell formation as the treatment of primary
human monocytes with 5µM oleoyl LPA for 16 hours increases oxLDL uptake measured
by oil red-O, and increases CD36 expression on the cell surface [124]. Additionally, it
appears as though the LPA-dependent upregulation CD36 only occurs when the human
CD36 promoter contains the PPAR responsive element suggesting LPA is a ligand for
PPARγ [124].

Identification of Novel Risk of CAD through Genome Wide Association Studies
(GWAS)
Once the human genome was sequenced a whole new avenue of identifying heritable risk
of disease opened up. Technology quickly permitted the sequencing of thousands of
individual genomes both faster and cheaper until present day GWAS are capable of
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generating massive quantities of genomic data on a population scale. More specifically,
genomes from populations of patients diagnosed with cardiovascular disease were
sequenced by SNP genotyping and compared to a healthy control population in order to
identify single nucleotide polymorphisms (SNPs) that could predict one’s increased risk of
disease. SNPs are the most common form of DNA variation that occur in individuals and
are single nucleotide differences. A SNP occurs, on average, once every 300 base pairs
which translates to roughly 10 million SNPs in the human genome [125]. By comparing
SNP frequency in patients with CAD versus healthy populations, scientists are able to
identify “risk alleles” or SNPs that associate with disease. A meta-analysis was published
in Nature Genetics in 2011 that compared the results of several GWAS studies looking at
CAD and identified 13 novel risk loci as well as reaffirming 10 previously identified SNPs.
One of these novel risk loci termed rs17114036 is located in the final intron of the gene
PPAP2B that encodes the lipid phosphate phosphatase 3 enzyme [4].
Polymorphisms in PPAP2B Associate with CAD
The novel risk locus in PPAP2B is found at 1p32.2. The risk allele is an adenine (A) with
a frequency of 0.91 while the other protective allele is a guanine (G) at a frequency of
0.09. rs17114036 bears a composite p-value of 3.81 x 10-19 suggesting a significant
correlation with disease and an odds ratio of 1.17[4]. Another important consideration is
that while three novel loci from this meta-analysis were found in genes that are associated
with traditional risk factors of CAD, the majority of SNPs, including rs17114036, are found
in gene regions that have no previous implication in the development of atherosclerosis.
GWAS are capable of identifying risk alleles pertaining to a particular disease; however,
the SNP reported may not be the particular locus causing the functional insult. Commonly,
SNPs or alleles exhibit non-Mendelian genetic patterns and tend to associate together in
nonrandom fashion with other SNPs in close proximity. This particular genetic
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phenomenon is known as linkage disequilibrium and a grouping of SNPs in linkage
disequilibrium is termed a haplotype. Rs17114036 is in linkage disequilibrium with roughly
20 proxy SNPs with an r2 of 0.81 or higher, any one of which could be the functional
disease-causing locus. This tendency to travel as a haplotype is important because of
subsequent investigations led by Jake Lusis at UCLA and Chris O’Callaghan at Oxford
looking into SNPs that are in linkage disequilibrium with rs17114036. Erbilgin et al.
identified a proxy SNP, rs6588635, which associates with the earlier identified SNP
rs17114036 at an r2 = 0.831. Utilizing this proxy SNP as a biomarker that is found to be in
linkage disequilibrium with the original rs17114036, the group from UCLA reported marked
changes in PPAP2B expression in human aortic endothelial cells (HAECs) relative to an
individual’s SNP genotype. In fact, individuals homozygous for the proxy SNP risk allele,
in this case a thymine (T), show marked decreases in expression relative to those who
are heterozygous (CT) suggesting that possessing the homozygous risk allele genotype
(TT) renders the HAEC unable to express PPAP2B to the same degree as heterozygotes.
Reschen et al. sought to identify regions of the genome that are subject to transcriptional
regulation following exposure to atherogenic stimuli such as oxLDL. In their study
published in PLOS Genetics in 2015, Reschen et al. demonstrated using FAIRE-seq and
ChIP-seq that the conversion of naïve human monocytes to foam cells via exposure to
oxLDL results in dramatic remodeling of open chromatin regions. One site in particular
harbors the SNP rs72664324 that lies within the gene PPAP2B. Sequencing the regions
of newly exposed open chromatin revealed that the aforementioned locus falls within a
C/EBPβ binding motif (CCAAT) and that the risk allele disrupts this motif (CCGAT)
rendering the transcription factor unable to bind. In collaboration with the group we looked
at PPAP2B expression of LPP3 in monocytes before and after oxLDL exposure. While
naïve monocytes show very modest levels of LPP3 protein, observed via immunoblot, and
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LPP3-dependent phosphatase activity, oxLDL treatment significantly increases both LPP3
levels and LPP3-dependent phosphatase activity roughly 3-fold. Similar to the HAECs
investigated by Lusis et al. [126], monocytes from individuals homozygous for the risk
allele exhibited a reduced ability to upregulate PPAP2B expression relative to
heterozygote monocytes following oxLDL treatment.
Large-scale GWAS analysis combined with independent research investigations into
genotype specific SNP activity in PPAP2B suggests that the risk alleles responsible for an
increase in an individual’s risk of CAD appear to be acting, at least in part, in a cis manner
by reducing the gene’s expression in various human vascular cells.

PPAP2B encodes Lipid Phosphate Phosphatase 3

PPAP2B encodes the protein LPP3 that belongs to a family of proteins known as lipid
phosphate phosphatases or LPPs. LPPs are transmembrane enzymes capable of
degrading various phospholipids such as lysophosphatidic acid (LPA), sphingosine-1phosphate (S1P), ceramide-1-phosphate (C1P), phosphatidic acid (PA), and a few others.
Structure and Function of the LPPs3
Structurally, the LPPs contain six transmembrane domains with 5 extramembrane loops
[127]. Their catalytic domains are found on the third and fifth loop facing the
extracellular/luminal surface and the LPPs’ enzymatic activity are dependent upon a
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Portions of this section were taken from Mueller et al. [15]. Some additions and

modifications to the text and figures have been made for clarity of information.
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variably glycosylated site on the third loop. Additionally, both the N- and C- termini are
located on the cytosolic surface (Figure 1.2). The LPP family consists of three proteins
LPP1, LPP2 and LPP3 encoded by the genes PPAP2A, PPAP2C and PPAP2B
respectively. Spatially speaking, the LPPs’ localization varies depending on the cell type
and degree of glycosylation, but can range from the endoplasmic reticulum, the Golgi, and
the plasma membrane. These proteins are capable of forming both hetero- and homo
oligomers in the plasma membrane while retaining enzymatic activity that is independent
of the other LPPs in the complex [128].
Although the three LPP enzymes demonstrate similar catalytic activities and substrate
preferences in vitro, the phenotypes of mice with targeted inactivation of the Ppap2 genes
establishes that their functions are non-redundant. Primary cells isolated from mice
harboring an exon trap inactivated allele of Ppap2a gene display a reduced ability to
dephosphorylate exogenously provided LPA, indicating a role for LPP1 as a cell surface
“ecto” LPA phosphatase [129]. Mice homozygous for an inactivated allele of the Ppap2c
gene, encoding murine LPP2, are phenotypically indistinguishable [130]. By contrast,
inactivation of Ppap2b results in embryonic lethality in part to due to failure of extraembryonic vasculature [131]. Media from cultured embryonic fibroblasts isolated from
Ppap2b-null mice contains 2.6-fold higher levels of LPA suggesting that the other LPPs
cannot compensate for the regulation of extracellular accumulation of LPA.
Mukherjee et al. published a study in 2013 demonstrating a role for the LPP3 homologs in
Drosophila, Wunen and Wunen2, in generating and regulating phospholipid gradients in
vivo [132]. Normally germ cells in the developing Drosophila embryo begin as a cluster of
cells at Stage 9, separate and migrate in an organized fashion into the mesoderm by Stage
12 where they partition bilaterally to interact with somatic gonadal precursor cells. As the
germ cells migrate they tend to avoid somatic tissues expressing wun and wun2
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suggesting that the phosphatases play a role in directing migration. In fact, when Wunen
and Wunen2 are knocked out in somatic tissues the germ cells’ migration pattern is
dramatically disrupted. Mukherjee et al. defined the maximum range of influence of
Wunen-expressing cells on germ cells as approximately 33µm.
LPP3 Modulates LPA-dependent Vascular Endothelial Cell (vEC) Function
LPP3 is clearly important in the development of multiple species, but its role in the mature
vasculature is less understood. As it turns out, endothelial cell-specific deletion of Ppap2b
is embryonically lethal due to vascular defects similar to what was observed in the Ppap2bnull mice [22]. To study the effects of endothelial deletion of LPP3 in a murine vascular
injury model, a tamoxifen-inducible model of endothelial cell-specific deletion was
achieved by breeding Ppap2bfl/fl mice to transgenic mice expressing a recombinant
estrogen receptor-Cre fusion protein under the control of the tyrosine kinase Tek promoter
(ERT2-Cre). Following LPS injections, mice targeted for endothelial cell deletion of LPP3
(ERT2-∆) displayed enhanced systemic inflammation detected by a 3.3-fold increase in
IL-6 and a 1.9-fold increase in KC compared to the control mice (fl/fl) suggesting that LPP3
in the endothelium is anti-inflammatory. ERT2-∆ mice also displayed marked differences
in endothelial barrier function compared to the fl/fl counterparts. Deletion of LPP3 in the
endothelial cells results in ~2.2-fold increase in vascular leakage as measured by Evans
blue dye (EBD) leakage into the lungs which is exacerbated when mice are injected with
LPS. This effect on endothelial barrier function is specific to endothelial cells and not the
hematopoietic deletion of LPP3 as ERT2-∆ bone marrow transplantation into fl/fl mice
showed no changes in EBD leakage whereas EBD leakage into the lungs of ERT2-∆ mice
harboring fl/fl bone marrow was pronounced. Finally, and potentially most importantly,
compromised endothelial barrier function in mice lacking endothelial LPP3 is ameliorated
upon the administration of either ATX inhibitors or a pan-LPA receptor antagonist
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suggesting that LPA signaling, at least in part, is responsible for this phenotype. Data from
Panchatcharam et al. strongly implicates a role for LPP3 in protecting endothelial barrier
function as well as systemic inflammation and that the former role is through the regulation
of LPA signaling [22].
Endothelial cell-specific deletion of LPP3 leads to a decrease in endothelial barrier
function in mice as quantified by EBD leakage into the lungs suggesting a physiological
role for LPP3 in maintaining vascular endothelial barrier integrity. In human umbilical vein
endothelial cells (HUVECs) LPP3 is localized in areas of cell-cell contact sites while it
appears absent in areas of non-contact sites [84]. Yukiura et al. showed in 2015 that
treatment of HUVECS with 1µM LPA induced stress fiber formation, increased the
incidence of intracellular gaps and increased endothelial cell permeability as measured by
leakage of FITC-labelled dextran across a monolayer of cells. LPP3 plays a critical role
regulating this LPA-induced stress fiber formation which appears to be signaling through
LPA6. Reducing LPP3 expression using PPAP2B-siRNAs results in HUVEC stress fiber
formation at a dose of 0.1µM LPA that is otherwise absent in cells treated with controlsiRNA. Additionally, silencing LPA6 using siRNA abolishes LPA-induced stress fiber
formation providing a mechanistic role for LPP3 in regulating LPA-induced endothelial cell
remodeling and vascular permeability.
Wu et al. demonstrated another potential role for LPP3 in maintaining vascular health in
2015 [83]. In atherosusceptible areas of the vasculature harboring disturbed blood flow
and low shear stress, PPAP2B appears to be downregulated in vECs by miRNA-92a. As
mentioned previously, disturbed flow and low shear stress alters the morphology and
alignment of vECs from a parallel alignment to the classic cobblestone arrangement
leading to increased vascular permeability, inflammation and expression of adhesion
molecules. By reducing

PPAP2B expression using siRNA in HAECs under
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atheroprotective (laminar) flow; HAECs take on the cobblestone morphology similar to
those in an atherosusceptible flow that is accompanied by increased expression of
inflammatory cytokines and adhesion molecules MCP1 and VCAM1 respectively.
Interestingly, use of the LPA receptor 1 and 2 antagonist ki16425 ameliorated MCP1 and
VCAM1 upregulation. These data allude to another mechanistic role for LPP3 in regulating
LPA-dependent remodeling of HAECs in the context of atherosusceptible blood flow.
LPP3 Limits Neointimal Hyperplasia and Inflammation in mice
Our lab has also identified a role for LPP3 in limiting the development of neointimal
hyperplasia following carotid artery ligation [133]. In wild-type mice, Ppap2b expression
significantly increases 7 and 28 days post-ligation and LPP3 levels are significantly
increased at 28 days post ligation while there is apparent elevation at 14 days. SMCspecific LPP3 deletion in mice (SM-Ppap2bΔ) resulted in ≈3- to 4-fold increases in the
intimal area compared to Ppap2bfl/fl mice 4 weeks after carotid artery ligation suggesting
that LPP3 limits the development of neointimal hyperplasia. Uninjured vessels from SMPpap2bΔ mice have marked downregulation of SMC markers Acta2, Tagln, Myh11, and
Cnn (≈1.8-, 2.3-, 3.9-, and 3.0-fold respectively) relative to the control mice. SMCs isolated
from the thoracic aorta of SM-Ppap2bΔ also demonstrate increased proliferation and
migration compared to controls.

Overview
There is little question that CAD is the leading cause of death in both men and women
worldwide and a major socio-economic burden in the United States. The multi-factoral
disease arises from both environmental and heritable insults that incorporate the
dysfunction of nearly all vascular-cell types and many other tissues as well. Significant
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evidence points to a role for the ATX-LPA-LPP3 axis in the development and progression
of atherosclerotic plaques in part because of their influence on so many of the vascular
tissues contributing to disease, but even more so is the considerable genomic data
implicating a risk loci in PPAP2B that confers an increase in CAD risk. The work presented
in this dissertation is to demonstrate 1) that Ppap2b expression limits atherosclerotic
lesion formation in a murine model of atherosclerosis (Chapter 2) 2) CAD associated riskalleles decrease expression of PPAP2B in a cis-dependent manner (Chapter 2 and 3) and
3) LPA content increases in plasma fractions containing atherogenic LDL-C in murine
models of hyperlipidemia and atherosclerosis.
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Table 1.1

Lesion Stage and Timeframe for Development in both Apoe-/- and Ldlr-/- Mice [77]
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Figure 1.1
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Lysophosphatidic acid. A potent lysophospholipid signaling molecule consisting of a
phosphate group bound to a glycerol backbone and a variable fatty acid chain that
signals through one of six known GPCRs (LPA1-6).
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Figure 1.2

Structure of lipid phosphate phosphatases. The LPPs contain six
transmembrane domains with 5 extramembrane loops [127]. Their catalytic
domains are found on the third and fifth loop facing the extracellular/luminal
surface and the LPPs’ enzymatic activity are dependent upon a variably
glycosylated site on the third loop. Additionally, both the N- and C- termini are
located on the cytosolic surface. Illustration by Matt Hazzard, University of
Kentucky, Information Technology.
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Chapter 2: Ppap2b Expression Regulates CAD in a Tissue-specific Manner
Introduction
CAD is the leading cause of death in both men and women worldwide and is defined as a
narrowing of the coronary arteries as a result of the growth and accumulation of
atherosclerotic plaques. The development of atherosclerotic lesions is a complex process
initiated by the deposition of LDL-C in coronary artery vessel wall and involves the
dysfunction of multiple vascular tissues as well as unchecked inflammation. Advanced
lesions harbor a highly prothrombotic necrotic core that, upon plaque rupture, is exposed
to the circulation, stimulating thrombosis and potentially MI. Risk of CAD has a strong
heritable component and advances in genome sequencing have identified upwards of 46
disease-associated loci many of which are independent of the traditional risk factors [134].
A meta-analysis of GWAS studies looking into CAD-associated SNPs identified a
noncoding polymorphism termed rs17114036 that confers an increase in risk of disease
[4]. Rs17114036 lies within the final intron of PPAP2B at chromosomal band 1p32.2, which
is on the same chromosome of the LDL-C regulator PCSK9 and could thus be acting in
trans affecting PCSK9 and cholesterol levels. Searching publically available databases
revealed a SNP in linkage disequilibrium with rs17114036 that shows allele-dependent
variations in the expression of PPAP2B, but not PCSK9, in peripheral blood cells
suggesting that the SNP is capable of acting in a cis-manner and is not changing PCSK9
expression (unpublished data; see Chapter 3). Supporting this data, the CAD-associated
risk allele correlates with decreased expression of PPAP2B in HAECs [126]; additionally,
it has been shown to inhibit C/EBPβ-dependent upregulation of PPAP2B in primary human
macrophages exposed to oxLDL by interrupting a CCAAT binding motif [135].
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PPAP2B encodes the protein LPP3, a member of the integral membrane protein LPP
family whose primary enzymatic function is the degradation of phospholipids such as LPA,
S1P, C1P, PA and others [136]. Germline deletion of LPP3 is embryonically lethal due to
vascular defects [137]; whereas the other LPPs show unremarkable phenotypes
suggesting a nonredundant role for LPP3 in development [138]. LPP3 homologs, Wunen
and Wunen2, play a large role in generating phospholipid gradients, up to a distance of
33μm, that is critical in directing the migration of germ cells [132]. Our lab has previously
identified a role for SMC-specific LPP3 in limiting neoinitimal hyperplasia and inflammation
in murine models of vascular injury [133]; as well as a role for endothelial cell-specific
LPP3 in maintaining vEC barrier function in murine models of systemic inflammation [22].
Furthermore, endothelial cell Ppap2b expression is downregulated in atherosusceptible
regions of murine aorta where turbulent blood flow drives phenotypic alterations and vEC
dysfunction [83]. Considering CAD-associated risk allele-dependent effects on PPAP2B
as well as LPP3’s role in murine vascular models of injury, systemic inflammation and
turbulent nonlinear flow, we hypothesize that LPP3 is protective in murine models of CAD.

Materials and Methods
Animals
All procedures conformed to the recommendations of Guide for the Care and Use of
Laboratory Animals (Department of Health, Education and Welfare publication number
NIH 78-23, 1996), and were approved by the Institutional Animal Care and Use
Committee. The production, initial characterization, and backcrossing of Ppap2bfl/fl mice
to a C57BL/6 background for >10 generations has previously been described [137, 139].
In order to generate mice susceptible to atherosclerosis, Ppap2bfl/fl were crossed to LDLr/-

mice obtained from The Jackson Laboratory (Bar Harbor, ME) to yield Ppap2bfl/fl LDLr-/-

mice. Generation of an atherosusceptible inducible global LPP3 KO mouse: To generate
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mice with an inducible global reduction in Ppap2b, female Ppap2bfl/fl LDLr-/- mice were
crossed to male Ppap2bfl/flLDLr-/-mice expressing Cre recombinase under the control of
the inducible MX-1 promoter to generate mx1-ppap2bΔ Ldlr-/- (referred to as MX-1Δ) mice
following polyinosinic-polycytidylic acid (pI:pC) treatment. pI:pC (Sigma Cat#P1530100mg) was dissolved in sterile 0.9% saline (concentration of 10mg/mL) and 50µL was
administered via i.p. injection between post-natal days 3 to 5. Littermates not harboring
Cre recombinase were used as controls. Generation of an atherosusceptible SMC-specific
LPP3 KO mouse: To generate mice with SMC-specific Ppap2b deletion, female Ppap2bfl/fl
LDLr-/- mice were crossed to male Ppap2bfl/flLDLr-/-mice expressing Cre recombinase
under the control of the SM22 promoter to generate sm22-ppap2bΔ (referred to as SM22Δ) mice. Littermates not harboring Cre recombinase were used as controls. Generation of
Leukocyte-specific LPP3 KO Mice: To generate mice with leukocyte-specific Ppap2b
deletion, female Ppap2bfl/fl mice were crossed to male Ppap2bfl/fl mice expressing Cre
recombinase under the control of the LysM promoter to generate lysm-ppap2bΔ (referred
to as LysM-Δ) mice. Littermates not harboring Cre recombinase were used as controls.
Mice were housed in cages with HEPA-filtered air in rooms on 12-hour light cycles, and
fed RD Western Diet (Research Diets Cat#D12079B) ad libitum for 12 weeks.
Immunoprecipitation of LPP3
10µL/sample of protein G Sepharose beads (GE Healthcare Cat# 17-0618-01) was
washed three times with cold 1x PBS, and then resuspended in 20µL/sample of 1x PBS.
Antibody (1mg/mL) was incubated with the protein G Sepharose beads for 1 hour at 4°C
with periodic mixing. The beads-antibody mixture were washed again three times with cold
1x PBS, and then resuspended in 20µL/sample of 1x PBS. 100µg of whole protein was
added to the beads-antibody solution and incubated for 1 hour at 4°C with periodic mixing.
The beads-antibody-protein mixture was once again washed three times with cold 1x PBS.
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Phosphatase activity assay
Protein G Sepharose beads bound to LPP3 protein were resuspended in 30µL of ddH2O,
20µL of 5x Assay buffer containing 50mM tris base and 5mM EDTA pH 7.4, and 50µL of
0.2mM C17-sphingosine-1-phosphate in 6.4mM Triton X-100. Samples were incubated at
37°C in an Eppendorf thermomixer at 1,400rpm for 10 minutes. The reaction was stopped
by adding 400µL of 0.1M HCl to each sample and placed on ice. Samples were then
processed for lipid extraction.
Lipid extraction for analysis via mass spectroscopy
500µL of sample in 0.1M HCl were added to a 12mL glass lipid extraction tube containing
1mL of chloroform, 2mL of methanol, and 50µL of 1µM D7-sphingosine-1-phosphate as
an internal standard. Samples in the lipid extraction tubes were vortexed for 5 minutes,
and then placed on ice/kept at 4°C for at least 1 hour. 1mL of chloroform and 1.3mL of
0.1M HCl was added to the lipid extraction tubes and vortexed again for 5 minutes. The
samples were centrifuged at 3,000×g for 10 minutes at room temperature, and the lower
aqueous was transferred to 4mL screw cap glass tube using a Pasteur pipette being
careful not to include the protein interphase. Samples were evaporated to dryness using
nitrogen in an N-evap under a fume hood. Once the samples were completely dried, 100µL
of methanol was added and the tubes were vortexed. Samples sat at room temperature
for 10 to 15 minutes and then transferred to an autosampler insert vial for analysis via
Agilent Zorbax C8 column and quantified by tandem mass spectrometry using an ABI
4000 QTrap hybrid linear ion trap triple quadrupole mass spectrometer. The mass
spectrometer was operated in selective reaction monitoring mode to measure lipid species
specific precursor product ion pairs with quantification accomplished by reference to
calibration curves generated using synthetic standards obtained from Avanti Polar Lipids
that were independently quantitated by phosphorous analysis as described previously.
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Quantification of Atherosclerosis
Aortas were cleaned of the adventitia and dissected from the aortic root to the iliac
bifurcation and stored in 10% formalin for 24 to 48 hours. After treatment with
paraformaldehyde, the aortas were transferred to a 0.9% Saline solution and stored at
4°C for at least one day. Aortas were cut open longitudinally, exposing the intimal surface,
and secured with pins to be photographed. Atherosclerosis was quantified on the intimal
surface of the aorta by an en face technique described previously [140].
Quantification of LPA and cholesterol from mouse aorta
Aortas were cleaned of the adipose tissue and dissected from the aortic root to the iliac
bifurcation. The aorta was cut 3mm below the left subclavian artery (this section of the
aorta is defined as the proximal aorta) and the tissue was weighed. Aortic roots were
homogenized in 0.5mL of 0.1M HCl and underwent lipid extraction as described
previously. Internal standards used for this experiment were C17-LPA, C17-LPC, and D7cholesterol. Levels of LPA and cholesterol were normalized the tissue weight. Note: S1P
was undetectable in the proximal aortic tissue.

Gene Expression Analysis of Proximal Aortas
Murine proximal aorta was collected as described above in the Quantification of LPA, and
cholesterol. Tissue was weighed and stored in RNAlater® Solution (Ambion AM7020) at 80°C. Proximal aortas were homogenized and treated with the Qiagen RNeasy Fibrous
Tissue Mini Kit (Qiagen Cat# 74704) for the extraction of RNA. 1.0µg of RNA was used
for the generation of a cDNA library using MultiScribe™ Reverse Transcriptase (Life
Technologies Cat#4311235). cDNA was diluted 1:10 and used in a reaction with the
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TaqMan® Fast Universal PCR Master Mix (2X) (Life Technologies Cat#4364103) with
VIC/FAM primers from Life Technologies designed for specific gene targets.

Immunoblotting of Proximal Aortic Tissue
Murine proximal aorta was collected as described above in the Quantification of LPA,
and cholesterol. Tissue was homogenized in lysis buffer containing: 50mM Tris Base;
500mM NaCl; 4mM MgCl2; 1% Triton X-100; 1mM PMSF protease inhibitor. Protein
concentrations were determined with the Pierce™ BCA Protein Assay Kit (Cat# 23225)
and 40µg of total protein was added to a 10% polyacrylamide gel which was then
transferred to a nitrocellulose membrane. Antibody dilutions were as follows: LPP3
(1:200) and beta-actin (1:5,000). Membranes were scanned using a Li-Cor Odyssey
scanner.

Isolating Plasma from Peripheral Blood in Mice
Peripheral whole blood was collected from mice via the retro-orbital vein while mice were
anesthetized with isoflurane. Whole blood was collected in a 1.5 mL Eppendorf tube
containing 10 µL of 0.5 M EDTA and 50 µL CTAD (BD Vacutainer Ref# 367947). Blood
samples were centrifuged at 12,000 rpm for 4 minutes and the plasma fraction collected.
Samples were placed on dry ice and subsequently stored at -80°C.
Measuring Total Cholesterol and Lipoprotein Cholesterol Distributions in Murine
Plasma
Total plasma cholesterol was measured using the Wako Diagnostics Cholesterol E Assay
(Wako Diagnostics Cat#439-175001) according to the manufacturer’s protocol. Plasma
lipoprotein cholesterol distributions were determined via fast-performance liquid
chromatography (FPLC). In short, 40µL of plasma from mice, diluted to a concentration of
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1mg/mL of total plasma cholesterol, was injected on to a Superose 6 FPLC column.
Cholesterol concentrations are determined by enzymatic colorimetric assay (Wako
Diagnostics) reading at 600nm as the elute flows off of the column.

Measuring Total Triglyceride Content in Murine Plasma
Total plasma triglycerides was measured using the Wako Diagnostics L-type TG M Assay
and the Multi-Calibrator Lipid Standard to generate a standard curve (Wako Diagnostics
Cat# 461-08992, 461-09092, 464-01601) according to the manufacturer’s protocol.

Measuring Phospholipid Content in Murine Plasma
50 µL of plasma was added to 450 µL of 0.1 M HCl and underwent lipid extraction as
previously described in “Lipid extraction for analysis via mass spectroscopy”

Isolation and Culture of Bone Marrow Derived Macrophages
Femur and tibia isolated from mice were cut at both ends and flushed with 5mL prewarmed (37 degree C) DMEM Glutamax media using a 25 gauge needle. Red blood
cells were lysed with 0.8% ammonium chloride in 1x PBS for 5 minutes. Media-cell
suspension was pressed through a 70μm nylon mesh filter and centrifuged at 1000×g for
5 minutes. The cell pellet was resuspended in DMEM Glutamax containing 10% FBS,
1% PenStrep and 10% L929 media then transferred to a 6 well plate at a concentration
of 1 million cells per well. After 72 hours the wells were washed with sterile 1x PBS and
cultured in DMEM Glutamax containing 10% FBS, 1%PenStrep and 10% L929 media.
Cells were cultured for 7 to 10 days while refreshing media every 2 to 3 days. Culture
conditions were 37°C at 5% CO2.

37

Isolation and Culture of SMCs
Mice were anesthetized terminally with isoflurane, then doused in 70% ethanol and cut
open from the abdomen through the thorax. A 20mL syringe attached to a butterfly needle
(21 G3/4 X12” Vacutainer BD Cat# 367281) was used to inject 20mL of 1x PBS (kept at
37ºC) into the left ventricle and the vascular systems was perfused with a minimum speed,
after cutting open the femoral artery or the artery near the kidney. The perfusion was
performed twice, with a total of 40mL sterile 1x PBS at 37°C perfusion. The aorta was
separated from surrounding tissue starting from the aorta arch until the kidney vessel.
Enough care was taken to isolate the aorta without any fat bodies and any other
surrounding tissue. After isolation, the aorta was placed in isolation buffer (60mm plate
having 4ml of pre-warmth to 37°C isolation buffer) and flushed with isolation buffer to
remove all the RBCs. The aorta was transferred into a new 60mm plate containing
isolation buffer. The dish was incubated at 37°C while the rest of the animals were
dissected. Once two aortas per 60mm dish were collected, they were subjected to 2.5mL
of collagenase digestion buffer (3.1mg – 3.9mg collagenase type II dissolved in 5ml of
isolation buffer kept at 37°C) to remove the adventitia. The digestion was done for 20
minutes at 37°C incubator on the rocker. After digestion, aortas were transferred to a new
60mm dish with fresh isolation medium. The adventitia was gently removed by pulling over
the other end or tearing it. Aortas were washed once again and kept in the fresh isolation
medium until all of them were done. Finally, two aortas were placed in a 60mm dish,
covered with 2.5ml DMEM media (25mM glucose with 10% FBS and 1% PenStrep) and
incubated at 37°C for 12 to 18 hours till next day. Culture conditions should be at 5% CO2.

On the next day the aortas were subjected to elastase and collagenase digestion using
2.5ml of digestion medium (containing elastase and collagenase) at 37ºC in a rotating
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rocker and after 22 minutes the aorta were gently sucked in a glass Pasteur pipette 15-20
times and once again placed in 37ºC. The whole digestion procedure was for 45min
including all the manipulation. 8ml of DMEM (25mM glucose, 10% FBS and 1% PenStrep)
was added to the digested aorta and centrifuged at 800rpm for 10min at 22ºC. The pellet
was plated in a 60mm dish containing 2.5ml of DMEM (25mM) with 10% FBS and 2.5ml
of proliferation media. Cells were gently aspirated and separated with a 10ml pipette and
left for 24hr. After 24hr (on the next day) the plate was washed 4 to 5 times with sterile
PBS and 2.5ml of DMEM (25mM) with 10% FBS and 2.5ml of proliferation media was
added again. Wait till confluence (takes three to four days). For RNA isolation use the
culture at about 70% confluence.

Aortic Root Sectioning and Immunofluorescent Imaging of Aortic Arches
Aortic roots were sectioned as described previously [141]. Hearts were excised, the aorta
was cut at its base as close to the heart as possible, and stored in OCT compound at 80°C. The hearts were cut horizontally ≈3mm from the base of the aortic root. The
remaining heart-aortic root was placed in a tissue mold with the root perpendicular to the
bottom surface of the mold and covered in OCT compound. The refrozen tissue block was
mounted to the cryostat chuck with the ventricular tissue facing outward. The ventricular
tissue was sectioned away until the aortic sinus is reached. Serial sections were collected
at 10μm/section, and 8 to 10 slides per aorta until the aortic wall was no longer visible.
Slides were stored at -20°C until used.

Microscope slides containing frozen tissue sections were submerged in chilled acetone
for 10 minutes and then incubated in Redusol 0.05% Cr3O3 for 2 minutes at 40°C. Slides
were washed 5 to 6 times in automation buffer (GeneTex Cat# GTX 30931) and then
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submerged in methanol containing hydrogen peroxide (3.2%) at 40°C for 2 minutes. Slides
were washed 5 times in automation buffer and incubated with Triton X-100 0 (0.5%) for
10 minutes at 40°C. Again, slides were washed 5 times with automation buffer and
incubated with the blocking agent (goat serum 15μL/mL) for 5 minutes at 40°C. Slides
were washed 5 times with automation buffer and incubated with the primary antibody for
20 minutes at 40°C. Primary antibodies used were LPP3 (Biosensis Cat# M-1560; 1:100),
Smooth muscle alpha-actin (Abcam Cat# ab5694; 1:100), CD68 (Abcam Cat# ab53444;
1:100), PECAM (BD Biosciences Cat# 553370; 1:100) and podocalyxin (R&D Systems
Cat# AF1556; 1:100). Slides were washed again 5 times in automation buffer and covered
in the immunofluorescent antibody (R&D Systems; 1:500) and incubated for 1 hour in the
dark at room temperature. Slides were washed 5 times in automation buffer and
submerged in Sudan Black (1% Sudan black in 70% EtOH) for 1 hour at room temperature
before a final wash with automation buffer and imaging. Imaging was performed using a
Nikon A1R confocal microscope with a spectral detector.

Statistical Analysis
All data are expressed as mean ± SEM unless otherwise noted. Statistical analysis was
performed using an unpaired, two-tailed Student t-test unless otherwise noted. P-value <
0.05 is regarded as significant. Two-way ANOVA was used when multiple comparisons
were made. Statistical analysis was performed using GraphPad Prism 7.
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Results
Noncoding SNPs Decrease oxLDL-induced PPAP2B Upregulation and Impair
C/EBPβ Binding
A meta-analysis of several GWAS investigations has implicated the gene PPAP2B in the
development of CAD in humans conferring an increase in risk of disease for those
harboring the risk allele. Rs17114036, the original risk loci implicated in the meta-analysis,
lies in a noncoding region of PPAP2B, specifically in the final intron. We provided
additional evidence by searching publically available microarray data and found that a
proxySNP (rs9970807) is associated with decreased expression of PPAP2B in peripheral
blood cell [142] – This is discussed in further detail in Chapter 3. Subsequent
investigations into SNPs in linkage disequilibrium with rs17114036 reveal HAECs
homozygous for the risk allele exhibit a diminished capacity to upregulate PPAP2B at
baseline as well as following treatment with oxPAPC relative to heterozygote cells;
therefore, the risk loci may act in a cis-manner on the gene in which it resides. A study
exploring changes in transcriptional regulation during the lipid-induced transition of
macrophages to foam cells identified rs72664324, in a noncoding region of PPAP2B,
which is subject to dramatic chromatin remodeling. This SNP is in linkage disequilibrium
with the CAD risk locus rs17114036 with an r2 > 0.8 and falls within a C/EBP binding
motif. As mentioned in the introduction, the risk allele G disrupts the CCAAT binding motif,
diminishing C/EBP binding, and correlates with lower PPAP2B expression relative to the
protective G allele.
In collaboration with Chris O’Callaghan’s group at Oxford, we demonstrated with Western
blotting that primary human macrophages display marked increases in LPP3 protein
following exposure to oxLDL compared to vehicle treatment (Figure 2.1a) LPP3-specific
phosphatase activity was significantly increased in oxLDL treated macrophages versus

41

vehicle controls determined by incubating immunoprecipitated LPP3 with LPA (Figure
2.1b) or S1P (Figure 2.1c) and measuring their respective product formation over time.
These data support O’Callaghan’s groups’ work demonstrating a functional role for oxLDLdependent C/EBP binding to the rs72664324 loci to potentially drive increased
expression of PPAP2B.
Risk loci in PPAP2B’s locus at 1p32.2 are also on the same chromosome as the master
LDL-C regulator PCSK9 at 1p32.3; therein, it is feasible that these risk loci are acting in
on PCSK9 expression because PCSK9 levels can dramatically impact circulating LDL-C,
and thus the development of atherosclerotic lesions. Looking at the previously mentioned
proxySNP, rs9970807, we found no association with the risk allele and PCSK9 expression
suggesting that SNPs in linkage disequilibrium with rs17114036 does not act on PCSK9
[142]. Evidence provided by our group, Jake Lusis’ and Chris O’Callaghan’s groups
demonstrate risk allele-dependent cis effects on PPAP2B expression. Considering LPP3’s
role regulating levels of LPA in addition to the ATX-LPA-LPP3 axis’ extensive impact on
vascular development, maintenance and pathogenesis it is conceivable that CAD-risk loci
in PPAP2B are acting in cis to confer increased risk of CAD through diminished levels of
LPP3.
LPP3 Expression is Upregulated in Mammalian Models of Atherosclerosis
Mounting genome-sequencing data has implicated PPAP2B in the risk of developing CAD
through the presence of risk allele associations. Indeed, SNPs in linkage disequilibrium
with rs17114036 display allelic-dependent variations in PPAP2B expression observed
through independent studies investigating different vascular tissues. LPP3 expression is
apparent in foam cells of human atheroma; however, little is known about its regulation in
the progression of CAD. C57BL/6 mice are resistant to hypercholesterolemia and thus the
development of atherosclerosis even on a high cholesterol diet and indeed display no
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signs of plaque formation in the aortic roots of mice after 12 weeks of Western diet (Figure
2.2 left panel). Apoe-/- mice are very susceptible to hypercholesterolemia and lesion
formation and following Western diet treatment show obvious upregulation of positive
LPP3 staining in the vessel lesions that is not observed in the IgG control (Figure 2.2
middle and right panels). To delineate cell-specific LPP3 localization we analyzed the
aortic roots of C57BL/6 mice and Ldlr-/- mice, another model of murine atherosclerosis,
after 12 weeks of Western diet. Immunofluorescent confocal imaging shows colocalization
of LPP3 with endothelial marker CD31 in C57BL/6 roots (Figure 2.3 top panel) consistent
with vEC expression of LPP3; however, no LPP3 staining was observed in the remaining
intima or media. Ldlr-/- aortic root lesions display pronounced positive LPP3 staining in
both the endothelial cells as well as throughout the vessel/lesion wall (Figure 2.3 bottom
panel). LPP3 also shows colocalization with SMC marker SMA (Figure 2.4 top panel) and
macrophage maker CD68 (Figure 2.4 bottom panel) in the subintima indicating
upregulation of LPP3 in these cells within atherosclerotic lesions. Colocalization of LPP3
and podocalyxin in Ldlr-/- roots (Figure 2.5) suggests, in endothelial cells, that LPP3 is
localized to the apical membrane. To determine if CAD-dependent LPP3 upregulation is
unique to mice, we examined LPP3 expression in porcine coronary arteries with
pronounced lesion formation. LPP3 expression is substantial and colocalizes with SMA
throughout porcine vessel lesions (Figure 2.6) suggesting that LPP3 is upregulated in
multiple mammalian species with CAD. Finally, to delineate that the upregulation of LPP3
is specific to atherosclerotic lesions and not just the vasculature of hypercholesterolemic
mice, we analyzed LPP3 protein in atherosusceptible (proximal aorta) and atheroprotected
(thoracic aorta) regions of murine aorta with Western blotting. Indeed, LPP3 was
upregulated only in the proximal aorta of Apoe-/- and LDLr-/- compared to the thoracic aorta
(Figure 2.7). Consistent with our observations in the C57BL/6 aortic roots, LPP3 levels
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were lower in the proximal aorta of wildtype mice, compared to its hypercholesterolemic
counterparts, and was comparable to the levels observed in the thoracic aorta.
We found that the rs17114036 and rs72664324 SNP regions in PPAP2B are conserved
in the mouse monocyte cell line RAW264.7 and that the rs17114036 locus serves as a
binding site for the transcription factor c-Fos. The monocyte cell line contains the risk allele
for rs72664324 (G/C) but the protective allele for rs17114036 (G/C). We designed major
(Hrs4324G/C, Mrs4324G/C, Hrs4036A/T) and minor (Hrs4324A/T, Hrs4036G/C) allelecontaining oligos with human and mouse DNA sequences containing the SNP regions and
performed DNA affinity precipitation assays. Western blotting of RAW264.7 nuclear
extracts that were immunoprecipitated with Hrs4324G/C (risk allele) did not display
binding to C/EBP; however nuclear extracts immunoprecipitated with Hrs4324A/T
(protective allele) did (Figure 2.8a), thus supporting the observations of Reschen et al.
[135]. Similarly, Hrs4036A/T (risk allele) did not exhibit c-Fos binding whereas Western
blots run with nuclear extracts immunoprecipitated with Hrs4036G/C (protective allele) and
Mrs4036G/C display c-Fos binding (Figure 2.8b). Development of CAD coincides with
increased expression of LPP3 in the SMCs and macrophages within lesions; additionally,
the CAD-associated risk loci are conserved in a mouse-derived cell line and murine
C/EBP and c-Fos transcription factors exhibit allele-specific binding to human and mouse
oligos containing the SNP alleles suggesting that the phosphatase may play a role in the
development and/or progression of disease.
Inducible Global Reduction of Ppap2b Increases Lesion Formation in Murine
Models of Atherosclerosis
Our lab has previously identified a role for endothelial-derived LPP3 in the maintenance
of vEC barrier function, in a LPA-dependent manner, and reducing inflammation in a
model of LPS-induced systemic inflammation in vivo; as well as a role for SMC-specific
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LPP3 decreasing neointimal hyperplasia and IL-6 expression following carotid artery
ligation in vivo. Seeing that LPP3 reduces vEC barrier dysfunction, limits neointimal
hyperplasia following injury and limits proinflammatory cytokine expression, all of which
are hallmarks of CAD, its upregulation in atherosclerotic lesions could be a vascular
mechanism to combat CAD. To test this hypothesis we examined the development of
atherosclerotic lesions in a murine model of CAD.
Both germline deletion and endothelial cell-specific deletion of Ppap2b are embryonically
lethal as described previously. In order to study the effects of a global reduction in LPP3
in the context of atherosclerosis we generated an inducible global knockdown of Ppap2b
by crossing Ppap2bfl/fl Ldlr-/- (referred to as fl/fl henceforth) mice with mice expressing Cre
recombinase under the control of the inducible MX-1 promoter to generate mx1-ppap2bΔ
Ldlr-/- (referred to as MX-1Δ) mice following pI:pC treatment at postnatal days 3 to 5. MX1-mediated knockdown of Ppap2b was confirmed through relative gene expression
analysis using qRT-PCR on bone marrow cells (Figure 2.9a). Upon weaning, mice were
placed on a Western diet for 12 weeks to induce hyperlipidemia and atherosclerotic lesion
formation. We used Western blotting to measure proximal aortic LPP3 and observed
diminished levels of the phosphatase in MX-1Δ mice compared to fl/fl controls (Figure
2.9b). Confocal immunofluorescent imaging of aortic root lesions shows colocalization of
LPP3 and vEC marker PECAM in fl/fl mice, which is absent in MX-1Δ mice (Figure 3.8c).
Ppap2b deficiency did not alter body weight in either male or female mice (Table 2.1) nor
was there a difference in blood pressure among fl/fl and MX-1Δ mice (Table 2.2)
determined by tail-cuff measurement. We next analyzed circulating plasma lipids using
enzymatic colorimetric assays provided by Wako Diagnostics and FPLC. There were no
differences in total plasma cholesterol or the cholesterol distribution (Figure 2.10a and b)
between MX-1 Δ and fl/fl controls; similarly, total plasma triglycerides remained
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unchanged (Figure 2.10c). LPP3 enzymatically inactivates a variety of bioactive
phospholipids such as LPA and S1P that are found in abundance in the plasma and are
known to alter vEC barrier function. We looked at levels of LPP3 substrates in the plasma
using HPLC MS/MS and found that MX-1Δ mice display significant increases in total LPA
(≈2.2-fold, p<0.001) and S1P (≈1.5-fold, p<0.01) but not LPC compared to controls (Figure
2.10d) indicating that global reductions in LPP3 alter its phospholipid substrates in the
circulation. MX-1Δ mice have 30% (p<0.01) increase in lesion formation in the proximal
aorta compared to the fl/fl control mice reported as percent of total area using en face
analysis (Figure 2.11a). Coinciding with the increase in atherosclerosis development, lipid
analysis of the proximal aortas revealed ≈2-fold increase in total LPA content (p<0.05)
compared to fl/fl mice (Figure 2.11b). Relative gene expression analyses in the proximal
aortas using qRT-PCR reveal ≈1.9-fold increases in expression of macrophage marker
Cd68 (p<0.05) in MX-1Δ mice and a trend towards increased proinflammatory Il-6 relative
to fl/fl control mice (Figure 2.11c). Confocal immunofluorescent imaging of aortic root
lesions from the MX-1Δ and fl/fl mice, in accordance to the Cd68 expression, appears to
show increased positive CD68 staining in the Ppap2b deficient mice (Figure 2.11d).
Leukocyte-adhesion molecule ICAM-1 expression is markedly upregulated in the lesions
of MX-1Δ mice compared to fl/fl as well (Figure 2.12).
Leukocyte-derived LPP3 Fails to Protect Against CAD
MX-1Δ lesions showed increased levels of ICAM-1 which is consistent with a
preponderance of macrophage infiltration into the vessel wall [55] and consistent with our
observations of increased CD68 staining in lesions and Cd68 expression in proximal aorta
of MX-1Δ compared to fl/fl mice. The inducible MX-1 promoter is expressed in epithelial
and endothelial cells throughout the body including aorta, liver, lung, spleen, etc. [citation];
it also shows pronounced expression in hematopoietic cells including monocytes.
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Because LPP3 expression is upregulated during the conversion of primary human
macrophages to foam cells in vitro [135] and global Ppap2b deficiency increases
macrophage markers in lesions we investigated whether leukocyte-specific expression of
LPP3 conveys protection against lesion formation in mice.
We generated a murine model of myeloid-specific deficiency in Ppap2b by crossing
Ppap2bfl/fl mice with mice harboring Cre recombinase under the control of the LysM
promoter to yield Lysm-ppap2bΔ offspring. We transplanted Lysm-ppap2bΔ (LysM-Δ) and
Ppap2bfl/fl bone marrow cells into lethally irradiated Ldlr-/- host mice (referred to as LysMΔ-LDLr and fl/fl-LDLr respectively for this study). LysM-mediated deletion of Ppap2b was
confirmed using relative gene expression analysis of bone marrow-derived macrophages
(BMDMs) (Figure 2.13a). As before, mice were fed Western diet for 12 weeks to induce
hyperlipidemia and lesion formation. LysM-Δ-LDLr mice show no change in plasma total
cholesterol compared to fl/fl-LDLr mice (Figure 2.13b). In contrast to observations in mice
with global reductions in Ppap2b, leukocyte-specific deficiency of Ppap2b did not alter
circulating levels of LPA; however, we did see an increase in total circulating S1P (p<0.05,
Figure 2.13c). Similar to our observations in human macrophages, BMDMs from Ppap2bfl/fl
mice treated with oxLDL (50μg/mL) for 48 hours show significant upregulation of Ppap2b
expression following treatment with oxLDL (Figure 2.13a). Ppap2b deficient foam cells
exhibit significantly increased levels of proinflammatory Il-1 and Il-12b (≈2.7-fold, p<0.01
and ≈6.4-fold, p<0.01 respectively) relative to BMDMs from Ppap2bfl/fl mice (Figure 2.13b).
En face analysis of the proximal aortas revealed no differences in atherosclerotic lesion
formation between LysM-Δ-LDLr mice and their fl/fl-LDLr controls (Figure 2.14) suggesting
that leukocyte-derived LPP3 is not sufficient to confer the same protection to
atherosclerosis as was observed in the MX-1 model. These data suggest that while
leukocyte-derived LPP3 alone is not sufficient to protect against the formation of
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atherosclerotic lesions, it does play a role in regulating foam cell LPA accumulation and
proinflammatory cytokine expression.
SMC-specific Ppap2b Expression is Athero-protective in Mice
We next investigated whether LPP3 expressed by SMCs alters the development of CAD
in mice. Utilizing Cre recombinase under the control of the SM22 promoter, we generated
SMC-specific knockout of LPP3 in mice on an Ldlr-/- background (SM22-Δ). SMCs were
isolated from the aorta of SM22-Δ and fl/fl mice and knockdown of Ppap2b was confirmed
with relative gene expression analysis using qRT-PCR (Figure 2.15a). Similar to the two
previously described mouse models, SM22-Δ and fl/fl mice show no differences in
cholesterol or total circulating LPA following 12 weeks on Western diet (Figure 2.15b and
c). A ≈2.7-fold increase (P<0.001) in lesion formation was observed in the proximal aorta
of SM22-Δ mice compared to fl/fl (Figure 2.16a). Analysis of the proximal aortas of these
mice reveal a ≈1.9-fold increase (p<0.05) in SM22-Δ total LPA content compared to fl/fl
controls (Figure 2.16b); as well as, ≈5.2-fold upregulation (p<0.05) of Il-6 expression in
SM22-Δ proximal aorta (Figure 2.16c). Confocal immunofluorescent imaging of aortic root
lesions display a pattern of increased CD68 staining in SM22-Δ lesions compared to fl/fl
controls (Figure 2.16d). These data implicate SMC-derived LPP3 in conferring protection
against atherosclerotic lesion formation in mice and reduced LPP3 in SMCs results in an
increase in proinflammatory Il-6 expression as well an increase in the area of CD68
positive cells.
Phenotypic Switching of Contractile SMCs to Foam Cells Increases C/EBPβ
binding in PPAP2B
SMC-derived LPP3 is known to limit the development of intimal hyperplasia and reduce
expression of inflammatory cytokine Il-6 in mice which very well may be the mechanism
of protection we see in our murine model of CAD presented in this study. Recent evidence
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indicates that SMCs contribute to foam cell populations in atherosclerotic lesions and up
to 50% of oil red-O stained cells in plaques may be of SMC origin [112, 120, 122].
Cholesterol loading of murine vascular SMCs in vitro causes a phenotypic switch of
contractile SMC to a foam cell-like state characterized by downregulation of contractile
SMC markers such as Acta2 and upregulation of macrophage marker Cd68 [112]. Our lab
has previously reported downregulation of Acta2 and Tagln in uninjured vessels from
Sm22-ppap2bΔ compared to Ppap2bfl/fl controls suggesting an absence of LPP3
contributes to dedifferentiation of SMCs [133]. We investigated whether PPAP2B
expression is altered in the phenotypic switching of a SMC to a foam cell in vitro.
Loading human coronary artery SMCs (caSMCs) with cyclodextran-cholesterol (10µg/mL)
for 72-hours (referred to as SMC foam cells) results in significant decreases in TAGLN
and ACTA2 (p<0.0001) as well as significant increases in CD68 expression (p<0.01) that
was not observed in vehicle treated SMCs (referred to as SMCs) (Figure 2.17a). SMC
foam cells exhibited a ≈2.4-fold increase (p<0.05) in PPAP2B expression compared to
SMCs (Figure 2.16b). SMC foam cells also display ≈3.0-fold upregulation (p<0.05) of IL-6
expression compared to vehicle treated controls (Figure 2.17b) suggesting heightened
inflammation from these cells.
SMC conversion to SMC foam cells results in a 2.3-fold increase (p<0.05) in CEBPB
expression whereas other transcription factors show no change (Figure 2.17c).
Interestingly, Western blotting with SMC foam cell nuclear extracts immunoprecipitated
with Hrs4324A/T (protective allele) and not Hrs4324G/C (risk allele, show C/EBP binding
that is not observed in the vehicle treated SMCs (Figure 2.18) indicating that cholesterol
loading induces C/EBP localization to the nucleus.

Discussion
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PPAP2B has been implicated in development of CAD due to the presence of noncoding
SNPs in the final intron of the gene that confers an increase in risk of disease [4]. A
proxySNP in linkage disequilibrium with rs17114036 is associated with decreased
PPAP2B expression in human peripheral blood cells [142]. HAECs homozygous for the
risk allele have a diminished ability to upregulate PPAP2B expression associated with
exposure to oxPAPC compared to heterozygote cells [126]. In this study we present data
obtained in collaboration with Chris O’Callaghan’s group at Oxford that demonstrates
human macrophages display an oxLDL-induced upregulation of LPP3 protein and LPP3associated phosphatase activity compared to vehicle treated macrophages (Figure 2.1).
LPP3 expression is also upregulated in models of vascular injury [22, 133] and limits
development of neointimal hyperplasia. We compared murine models of atherosclerosis,
Ldlr-/- and Apoe-/- mice, to C57BL/6 wildtype mice, which are known to be resistant to
hyperlipidemia and lesion formation. LPP3 expression appears absent in the vessel
subintima and media of C57BL/6 mice but is dramatically upregulated in Apoe-/- and Ldr-/lesions as well as atherosusceptible regions of the proximal aorta compared to
atheroprotected thoracic aorta (Figure 2.2, 2.3 and 2.7). We also demonstrated murine
C/EBP binding to the protective allele of rs72664324 and an additional transcription
factor, c-Fos, which binds to the protective allele of rs17114036 (Figure 2.8). We
hypothesized that LPP3 is protective in murine models of atherosclerosis. Using a model
of global reduction of Ppap2b expression driven by Cre Recombinase under the control of
the MX-1 promoter we generated adult animals with reduced LPP3 expression on the Ldlr/-

background. MX-1Δ mice developed larger lesion formation (Figure 2.11a) despite no

differences in circulating cholesterol levels (Figure 2.10a). To test whether there is a cellspecific effect we generated mice with leukocyte-specific and SMC-specific deletion of
Ppap2b. LysM-Δ-LDLr mice show no differences in development of atherosclerosis after
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12-weeks on Western diet (Figure 2.14). Contrary to LysM-Δ-LDLr mice, SM22-Δ mice
displayed greater atherosclerotic lesion formation compared to controls (Figure 2.16a)
implicating SMC-derived LPP3 as a protective agent in the context of CAD. Finally, we
examined the expression of PPAP2B in the phenotypic switching of primary human SMCs
to SMC foam cells. Similar to observations in primary human macrophages, caSMCs
upregulate PPAP2B expression 2.4-fold compared to controls (Figure 2.17b). CEBPB
expression is increased 2.3-fold in SMC foam cells compared to SMCs (Figure 2.17c) and
treatment of caSMCs with cyclodextran-cholesterol, to drive the phenotypic switch,
stimulates C/EBP-β binding to the rs72664324 protective allele (Figure 2.18) suggesting
similar epigenetic changes in chromatin structure may be affecting C/EBP-dependent
PPAP2B expression in SMCs that were observed in primary human macrophages.
Disease-associated noncoding SNPs identified in GWAS analyses carry out their
mechanism of action in either a cis- or trans-manner. Cis-acting SNPs typically alter the
expression of the gene in which they reside, are at least 1Mb proximal to the start of the
gene or are at least 1Mb distal to the end of the gene; whereas trans-acting SNPs are
capable of changing the expression of genes up to anywhere else in the genome and have
been shown to act on genes upwards of 50Mb away [143]. Rs17114036 in PPAP2B is at
locus 1p32.2, which happens to be on the same chromosome as the master LDL-C
regulator PCSK9 at locus 1p32.3. PCSK9 binds LDLr driving internalization and
subsequent lysosomal degradation of the LDLr-PCKS9 complex [144]. Decreased LDLr
in the liver leads to increases in plasma LDL-C; in fact, individuals with gain-of-function
mutations in PCSK9 are classified as having familial hypercholesterolemia, have profound
levels of circulating LDL-C and experience premature development of CAD between ages
30-40 [145]. Despite evidence from microarray databases demonstrating no altered rs9970807-dependent PCSK9 expression it is still conceivable that rs17114036 could act
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as a trans-regulator of PCKS9 and increase risk of disease by altering LDL-C. In this study
we demonstrate a protective role for LPP3 in the development of atherosclerotic lesion
formations in mice on an Ldlr-/- background. By using mice deficient in the LDLr we can
eliminate any PCSK9-dependent effects that is confirmed in our models by observing
LPP3-dependent protection in CAD, which despite no differences in circulating cholesterol
levels (Figures 2.10a and 2.15b). Taking into consideration that CAD-associated risk
alleles are associated with diminished expression of PPAP2B and that reductions in
Ppap2b in mice result in exacerbated lesion formation independent of PCSK9-mediated
alterations in cholesterol we posit that CAD-associated rs17114036 confers its increased
risk of disease through a cis-regulatory effect on PPAP2B.
In a study published in PLOS Genetics in 2015, Reschen et al. [135] investigated changes
in transcriptional regulation induced during the oxLDL-induced conversion of
macrophages to foam cells, a critical process in the progression of CAD [135].
Formaldehyde-assisted inducible regulatory element sequencing (FAIRE-seq) analysis
reveals dynamic remodeling of open chromatin regions throughout the genome including
in a region of PPAP2B, which harbors rs72664324. Rs72664324 is in linkage
disequilibrium with CAD risk-associated allele rs17114036 with an r2 >0.8 and happens to
be in a CCAAT binding domain for the transcriptional regulator C/EBP-β. The risk allele
interrupts the binding motif and inhibits oxLDL-induced C/EBP-β binding; subsequently,
upregulation of PPAP2B expression in the conversion of human macrophages to foam
cells was diminished in cells homozygous for the CAD-risk allele (GG) compared to cells
that were heterozygotes (AG). SMC-specific LPP3 expression limits the development of
atherosclerotic lesions in our model implicating the phosphatase as being protective in
CAD. PPAP2B upregulation in foam cells may be an intrinsic means of protection although
the mechanism remains to be described. In the present study we show that primary human
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caSMCs show similar upregulation of PPAP2B expression and cholesterol-dependent
C/EBP-β binding to rs72664324 (2.17b and 2.18) that was observed by Reschen et al. in
primary human macrophages, albeit an allelic-dependent variation in PPAP2B expression
should still be confirmed. Because SMC-derived LPP3 is sufficient to confer protection
against lesion formation in mice, and that C/EBP binding to rs72664324 is inhibited in
macrophages homozygous for the CAD-associated risk allele, it is feasible that individuals
homozygous for the rs17114036 risk allele are at greater risk of developing CAD due
inhibited C/EBP-dependent upregulation of PPAP2B in vascular SMCs.
In this study we demonstrate a protective role for LPP3 in the development of lesion
formations in a murine model of atherosclerosis. Global reductions in LPP3 resulted in
increased lesion formation (Figure 2.11a) independent of changes in cholesterol (Figure
2.10a). The MX-1 promoter is inducible in a wide range of epithelial cells throughout the
body including liver, lungs, spleen, aorta, and hematopoietic cells [146]. Confocal
immunofluorescent staining showed MX-1-mediated deletion of Ppap2b in the vEC of
aortic root lesions (Figure 2.9c). MX-1Δ mice also showed significant increases in total
LPA in their circulation and their proximal aortas compared to fl/fl controls. Our lab has
previously identified a role for endothelial cell-specific LPP3 in maintaining vEC barrier
function [22]. vEC-specific deletion of Ppap2b increased vascular permeability which could
be ameliorated with a pan-receptor antagonist BrP-LPA and the ATX inhibitor PF8380
suggesting that LPA signaling is mediating the LPP3-dependent barrier dysfunction.
Similar reports on LPA1 and LPA6 suggest that LPA induces vEC barrier dysfunction and
that siRNAs targeting LPP3 exacerbate the LPA6-dependent cytoskeletal changes in
HUVEC cells [84]. Considering the role of vEC dysfunction in the development and
progression of CAD, it is feasible that MX-1Δ mice develop increased lesion formation
through an LPP3-LPA dependent increase in vEC barrier permeability. Similarly,
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increased lesion formation in SM22-Δ mice coincided with increased total LPA content in
the proximal aorta compared to fl/fl controls (Figure 2.16b). Our lab has previously
identified a role for LPP3 in regulating LPA-dependent SMC migration and proliferation.
Presumably, the decreases in SMC-LPP3 could confer LPA-dependent migration and
proliferation of vascular SMCs driving an increase the lesion development in these mice.
We propose a model of LPP3-dependent protection against the development and
progression of CAD in mice that is independent of cholesterol and LDLr effects and that
individuals harboring CAD-associated risk alleles in PPAP2B are at greater risk of disease
due to a diminished ability to upregulate LPP3 expression (Figure 2.17).
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Table 2.1

Global deletion of LPP3 does not affect body weight. Mice were placed on Western
diet for 12 weeks in order to induce hyperlipidemia and development of atherosclerosis.
Prior to take down, mouse weights were recorded with respect to sex.

55

Table 2.2

Global deletion of LPP3 does not alter blood pressure. Blood pressure was recorded
using the non-invasive CODA® tail-cuff blood pressure system. 25 blood pressure
readings were taken from each mouse every day for 5 days and averaged. Daily
averages were then used to determine the average blood pressure reading for each
mouse.
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Figure 2.1

oxLDL increases LPP3 expression and LPP3-specific phosphatase activity. (A)
Primary human macrophages were treated with oxLDL (50µg/mL) for 48 hours and LPP3
protein was determined by Western blotting and normalized to beta-actin. (B and C) LPP3
was immunoprecipitated from vehicle or oxLDL treated macrophage lysates (n=3 donors
per condition) and phosphatase activity was determined by LC MS/MS from samples
incubated with (B) LPA and measuring the generation of MAG or (C) incubating with S1P
and measuring sphingosine generation. Data shown are mean ± SEM. *P<0.05 by
unpaired Student’s t-test.
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Figure 2.2

LPP3-positive staining is upregulated in Apoe-/- atherosclerotic lesions. C57BL/6
wildtype mice and atherosusceptible Apoe-/- mice were fed Western diet for 12 weeks.
Immunohistochemical staining of aortic roots of type mice and Apoe-/- mice was performed
with rabbit anti-LPP3 (Left and Middle) or rabbit anti-IgG (Right) as an immunoglobulin
control. Scale bar = 300µm.
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Figure 2.3

LPP3 expression in LDLr-/- mouse atherosclerotic lesions compared to C57BL/6
mice. (Top) C57BL/6 wild-type mice and (Bottom) Ldlr-/- mice were fed Western diet for
12 weeks. Aortic root sections were stained for LPP3 (Green) and endothelial marker
PECAM (Red) as described in Materials and Methods. Scale bar = 100µm.
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Figure 2.4

LPP3 colocalizes with SMCs, and macrophages, in LDLr-/- mouse atherosclerotic
lesions. Aortic root sections from Ldlr-/- mice fed Western diet for 12 weeks were stained
with LPP3 (Green) and macrophage marker CD68 (red; top) or SMC marker smooth
muscle alpha-actin (Red; bottom) as described in Materials and Methods. Scale bar =
100µm
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Figure 2.5

LPP3 localizes to the apical membrane of aortic endothelial cells. Aortic root sections
from Ldlr-/- mice fed Western diet for 12 weeks were immunofluorescently stained with
antibodies to LPP3 (Green) and apical membrane marker podocalyxin (Red) as described
in Materials and Methods. Scale bar = 100µm
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Figure 2.6

LPP3 is abundantly expresesed in porcine atherosclerotic lesions. Aortic root
sections from Ldlr-/- mice fed Western diet for 12 weeks were immunofluorescently stained
with antibodies to LPP3 (Green) and SMC marker smooth muscle alpha-actin (Red) as
described in Materials and Methods. Scale bar = 100µm
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Figure 2.7

LPP3 expression in atherosusceptible regions of murine aorta. LPP3 in
atherosusceptible proximal aorta and atheroprotected thoracic aorta of C57BL/6 wild-type,
Ldlr-/- and Apoe-/- mice (n=3 tissue from each genotype was pooled) was measured by
immunoblot analysis (Top). LPP3 at ≈37kD was normalized to beta-actin at ≈42kD as
described in the Methods and Materials. (Bottom) Western blot quantification normalized
to beta-actin. Data presented as mean ± SEM.
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Figure 2.8

C/EBPβ binding in mouse monocyte cell line RAW264.7 RAW264.7 cells were
treated with oxLDL (50μg/mL) for 24 hours. Transcription factor binding determined by
DNA affinity precipitation assay (DNAP) using biotin-labeled oligos for rs72664324 risk
and protective alleles and rs17114036 risk and protective alleles with nuclear extracts as
described in Materials and Methods. After DNAP, C/EBPβ (Left) and c-Fos (Right)
binding was determined with Western blotting.
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Figure 2.9

Reduced Ppap2b expression in bone marrow and proximal aorta from MX-1Δ mice.
Ppap2bfl/fl mice without (fl/fl) or with Mx1-Cre transgene (MX-1Δ) on Ldlr-/- background
were injected with pI:pC (50μL of 10mg/mL) between postnatal days 3 and 5. (A) Bone
marrow cells were isolated from the femurs of MX-1Δ and fl/fl mice (n=3 of each genotype)
and qRT-PCR analysis was performed as described in Methods and Materials. Data are
presented as mean ± SEM. *P<0.05 determined by Students t-test. (B) Following 12
weeks on Western diet, protein lysates from the proximal aortas of MX-1Δ and fl/fl mice
were analyzed by Western blotting. LPP3 levels were quantified by normalizing to betaactin as described previously. Data are presented as mean ± SEM. P<0.05 determined by
Students t-test. (C) Aortic root sections fl/fl and MX-1Δ were stained with
immunofluorescent antibodies to LPP3 (Red) and PECAM (Green) as described in
Materials and Methods.
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Figure 2.10

Global reductions in Ppap2b alter LPP3-specific plasma phospholipid substrates
but not cholesterol or triglycerides. Peripheral blood was collected from mice via
retro-orbital vein. (A) Total circulating cholesterol was measured using enzymatic
colorimetric assays from Wako Diagnostics (n=14 fl/fl; n=15 MX-1Δ). (B) Plasma
cholesterol (20μg) was separated by size exclusion chromatograph as described in
Methods and Materials. Cholesterol detected at 600nm is reported (mg/dL) over time
(seconds) (C) Total plasma triglycerides were measured using enzymatic colorimetric
assays from Wako Diagnostics (n=7 fl/fl; n=9 MX-1Δ). (D) Plasma lipid content (from
50μL plasma) was determined using LC MS/MS as previously described (n=15 mice per
genotype). Data are represented as mean ± SEM. **P<0.01; ***P<0.001 determined with
Students t-test.
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Figure 2.11

Global reduction of LPP3 increases atherosclerotic lesion formation and CD68
expression in murine aorta. Mice were fed Western diet for 12 weeks (A)
Atherosclerosis was quantified using the en face technique in proximal aorta (n=12 fl/fl;
n=14 MX-1Δ). Values are reported as lesion percent of the proximal aorta area (% Arch
Area). Individual percent and mean ± SEM are presented. (B) Proximal aortas were
homogenized and subjected to lipid extraction and LC MS/MS as described in materials
and methods. (C) Gene expression analysis by qRT-PCR from proximal aorta. (D) Aortic
root sections from MX-1Δ and fl/fl were immunofluorescently stained with antibodies to
LPP3 (Red), SMA (Blue) and CD68 (Green) as described in Materials and Methods.
Data are presented as mean ± SEM. *P<0.05 determined by Student’s t-test.
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Figure 2.12

LPP3 limits ICAM-1 expression in murine models of atherosclerosis. Mice were fed
Western diet for 12 weeks. Aortic root sections from MX-1Δ and fl/fl were stained with
antibodies to ICAM-1 (Green).
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Figure 2.13

OxLDL-induces upregulation of Ppap2b in murine macrophages and deletion of
leukocyte-specific LPP3 does not alter plasma cholesterol. (A) Bone marrowderived macrophages were isolated from fl/fl and LysM-Δ mice femurs and cultured as
described in methods and materials. Macrophages were treated with vehicle, LDL
(50μg/mL) or oxLDL (50μg/mL) for 48 hours. Expression was analyzed by qRT-PCR for
(A) Ppap2b. ***P<0.001; ****P<0.0001 determined by two-way ANOVA. (B) Il1b and
Il12b expression. **P<0.01 determined by Student’s t-test. (C) Total circulating
cholesterol was measured using enzymatic colorimetric assays from Wako Diagnostics
(n=9 fl/fl; n=10 LysM-Δ). Data are presented as mean ± SEM. *P<0.05 determined by
Student’s t-test. (D) Lipids were extracted from 50μL of plasma (n=10 mice per
genotype) and lipid content was determined using LC MS/MS as previously described.
Data are presented as mean ± SEM. *P<0.05 determined by Student’s t-test.
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Figure 2.14

Leukocyte-specific LPP3 does not limit lesion formation in mice but does
upregulate proinflammatory cytokines in foam cells. Mice were fed Western diet for
12 weeks. Atherosclerosis was quantified using the en face technique in proximal aorta
(n=10 fl/fl; n=10 LysM-Δ). Values are reported as lesion percent of the proximal aorta
area (% Arch Area). Individual percent and mean ± SEM are presented.
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Figure 2.15

SMC-specific deletion of Ppap2b does not alter circulating lipids. (A) SMCs were
isolated from fl/fl and SM22-Δ mice aortas and cultured as described in methods and
materials. Ppap2b expression was determined by qRT-PCR. (B) Total circulating
cholesterol was measured using enzymatic colorimetric assays from Wako Diagnostics
(n=8 fl/fl; n=7 SM22-Δ). (C) Lipid content from 50μL of plasma was determined using LC
MS/MS as previously described (n=10 fl/fl; n=10 SM22-Δ). Data are presented as mean
± SEM.
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Figure 2.16

SMC-specific LPP3 limits the development of atherosclerotic lesions in mice. Mice
were fed Western diet for 12 weeks (A) Atherosclerosis is quantified using the en face
technique in proximal aorta (n=10 fl/fl; n=7 SM22-Δ). Values are reported as lesion
percent of the proximal aorta area (% Arch Area). Individual percent and mean ± SEM
are presented. B) Lipid content from proximal aorta determined by LC MS/MS as
described in Materials and Methods. (C) Proximal aorta gene expression determined by
qRT-PCR analysis. (D) Aortic root sections from MX-1Δ and fl/fl were stained with
antibodies to LPP3 (red), SMA (blue) and CD68 (green) as described in Materials and
Methods. Data are presented as mean ± SEM. P<0.05 determined by Student’s t-test.
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Figure 2.17

SMC to foam cell phenotypic switching increases PPAP2B expression in human
caSMCs. Human caSMCs are treated with vehicle or cyclodextran-cholesterol
(10μg/mL) for 72 hours. (A, B and C) Gene expression determined by qRT-PCR
analysis as described in Materials and Methods. Data are presented as mean ± SEM.
*P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 determined by Student’s t-test.
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Figure 2.18

Primary human caSMCs exhibit cholesterol-induced C/EBPβ binding to the CADassociated protective allele. Human caSMCs were treated with cyclodextrancholesterol (10μg/mL) for 72 hours. DNA affinity precipitation assay (DNAP) was
performed by incubating biotin-labeled oligos for rs9970807 risk and protective alleles
and rs72664324 risk and protective alleles with nuclear extracts as described in
Materials and Methods. After DNAP, C/EBPβ binding was determined with Western
blotting.
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Figure 2.19

Accumulation of oxLDL in atherosusceptible vessel walls stimulates C/EBP binding to
the SNP region of PPAP2B to drive expression of LPP3. However, presence of the CADassociated risk allele impedes this upregulation by breaking C/ETP’s binding motif
leaving the vessels prone to unchecked inflammation and progression of
atherosclerosis.
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Chapter 3: Peripheral Blood does not Upregulate PPAP2B Expression
Following Acute Myocardial Infarction

Introduction
Acute myocardial infarction (acute MI) is a leading cause of morbidity and mortality
worldwide. Acute MI is said to occur when myocardial ischemia, a lack of blood supply to
the heart tissue, overwhelms myocardial repair mechanisms that maintain normal
myocardial cell function and homeostasis ultimately resulting in irreparable ischemiainduced damage and death of the myocardium most distal to the infarct site.
Atherosclerotic plaque rupture resulting in the generation of an intracoronary thrombus is
the most common cause of acute MI [147]. CAD is defined as a narrowing of the coronary
blood vessels as a result of the accumulation of atherosclerotic plaques. These lipid-laden
plaques develop throughout life and as early as the first decade in atherosusceptible blood
vessels and are initiated by the deposition of LDL-C within the tunica intima [52, 53]. LDLC is modified to a proinflammatory oxLDL microparticle that triggers vEC activation and
subsequent recruitment of leukocytes such as monocytes and neutrophils [55, 56]. While
the role of neutrophils in CAD is uncertain, monocyte/macrophage conversion to foam
cells is a well-understood phenomenon that generously contributes to the progression of
disease. As individuals’ age, CAD progresses, and early lesions marked by fatty streaks
develop into complex atheroma with a highly thrombotic necrotic core laden with oxidized
lipids underlying a tough fibrous cap that grows into the vessel lumen [51-53]. If rupture
occurs there is potential for generation of an intracoronary thrombus, with platelet
deposition, white blood cell accumulation with our without fibrin formation that can
ultimately result in acute MI.
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CAD is the leading cause of death in both men and women worldwide and carries with it
a wide range of risk factors. Modifiable risk factors for CAD include poor nutrition
(development of type II diabetes), sedentary lifestyle, tobacco use, hypertension and high
LDL-C [49, 50]. The latter two can be modifiable with appropriate medication. Nonmodifiable risk factors include the male sex, age, and inherited genetic risk. Analyses of
GWAS have revealed up to 47 distinct genetic risk loci that associate with an increased
risk of CAD [134]. A meta-analysis published in 2011 identified a genetic risk locus; a
noncoding SNP termed rs17114036, in the gene PPAP2B conferring an increase in risk
of CAD [4]. SNPs identified from GWAS are not necessarily the disease-causing locus but
may merely be in linkage disequilibrium with the culprit polymorphism; therefore
polymorphisms in close proximity to the GWAS-identified SNP (proxySNPs) in high
linkage disequilibrium (r2>0.8) should also be considered. Additionally, noncoding SNPs
implicated in disease may confer their risk through cis-mediated effects on the gene they
reside or are nearest to, or through trans-mediated effects on genes anywhere else on the
chromosome.
PPAP2B encodes LPP3, a member of the LPP family responsible for dephosphorylating
bioactive phospholipids such as LPA, S1P, C1P, and PA. Our lab has previously identified
tissue-specific roles for LPP3 in maintaining vEC barrier function [22] as well as limiting
neointimal hyperplasia following vascular injury [133].
In the current chapter we examined expression of PPAP2B in blood cells in healthy
volunteers and in patients suffering from acute MI. First, we examined LPP3 expression
in human blood cells. Then, we identified, using publically available microarray data [142,
148], a proxySNP in linkage disequilibrium with rs17114036 (r2>0.901) that is associated
with decreased expression of PPAP2B in peripheral blood cells [142]. We failed to observe
allele-dependent variation in LPP3 expression in neutrophils from volunteers either
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homozygous or heterozygous for the rs17114036 risk allele. Finally, investigating PPAP2B
expression in the peripheral blood from patients with acute MI, stable ischemic heart
disease (SIHD) or healthy volunteers reveals no significant changes in expression among
the three cohorts.

Materials and Methods
Patients and study design
This study was approved by the University of Kentucky Institutional Review Board
(Protocol #: 11-0367). Subjects were asked to donate blood for research purposes. 30 –
50 cc of venous blood was collected by phlebotomy. Normal volunteers were at least 18
years old were recruited from laboratory and staff personnel by word-of-mouth. Women
and minorities were included. Children were excluded because they are not routinely
employed as laboratory or staff personnel and because they are not a patient population
that normally develops CAD. Individuals with acute MI were recruited from the cardiac
catheterization laboratory at UK Chandler Medical Center, from the cardiology outpatient
clinics at the Gill Heart Institute and the UK Good Samaritan Professional Building.
Patients with SIHD were referred by their treating physician.

Genotyping of LPP3 rs17114036 polymorphism
DNA isolated from peripheral whole blood is collected from healthy donors as well as
patients that have consented to participate in the IRB approved study protocol. DNA was
isolated from whole blood (300µL) using the Maxwell® 16 Blood DNA Purification Kit
protocol (Promega Cat# AS1010). Genotyping was performed according to the TaqMan
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SNP Genotyping Assay for rs17114036 (Life Technologies Cat# 4351379) with an Applied
Biosystems 7500 Fast Real-Time PCR System, 11.25µL of DNA along with 12.50µL of
TaqMan Universal Mix (2x) and 1.25µL of 20x SNP assay primers were added to a
MicroAmp® Fast Optical 96-well reaction plate (Life Technologies Cat#4346906). The
plate was run using the “SNP Genotyping Assay” configuration on the RT-PCR software.
Donors were classified as being homozygous for the risk allele (A/A), heterozygous (A/G),
or homozygous for the protective allele (G/G).
RNA quantification of PPAP2B from human whole blood
RNA isolated from peripheral whole blood was collected from healthy donors as well as
patients. RNA was isolated from whole blood (300 – 500µL) using RiboPure™ RNA
Purification Blood Kit (Life Technologies Cat# AM1928) protocol. RNA was treated with
DNase for the removal of DNA contaminates (provided in the RiboPure™ blood kit). 1.0µg
of RNA was used to generate a cDNA library using the SuperScript® VILO cDNA
Synthesis Kit (Life Technologies Cat# 11754-050). RNA samples in the SuperScript®
reaction mix were incubated at 25°C for 10 minutes, 42°C for 60 minutes, and the reaction
terminated at 85°C for 5 minutes. 1.0µg of cDNA was used for qRT-PCR using primers
designed for generated a 65bp amplicon in PPAP2B spanning exons 1 and 2 (Life
Technologies Cat# 4331182 Hs00170359_m1). qRT-PCR was performed on the Applied
Biosystems 7500 Fast Real-Time PCR System. Transcript copy number of PPAP2B was
determined using a copy number calibration curve generated using serial dilutions of a
copy number control designed for the region of PPAP2B for which the aforementioned Life
Technologies’ primers span as described below. Relative gene expression is quantified
using the ΔΔCT method using ribosomal 18s as an endogenous control.
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Generation of a copy number calibration control for qRT-PCR analysis of PPAP2B
In order to generate an amplicon that was detected by the qRT-PCR primers obtained
from Life Technologies, oligo primers were designed to cover >70 base pairs in both
directions starting from the border of exons 1 and 2 of PPAP2B (Operon Forward Primer:
AACAACAACCCGAGGAGGAG; Reverse primer: GCAGTAAAACCCTCGGTGGT). PCR
cycle set up: 94°C for 1:00 minute; [94°C for :30; 60° for :30; 72° for :30] x 35 cycles; 72°
for 2:00 minutes. PCR amplicons generated from this PCR were run on a 1% agarose gel
at 100mV until the bands were detectable at their expected size of 138bp. The DNA bands
were cut from the gel and weighed. In a 1.5mL Eppendorf tube, the gel-DNA bands were
treated with 3 volumes of Qiagen Buffer QG (Qiagen Cat#19063) for 1 volume of gel
(300µL Qiagen buffer for every 100mg of gel). Samples were incubated at 55°C for 10:00
minutes with frequent vortexing. Once the gel was dissolved, 1 volume of 100%
isopropanol was added for every 1 volume of gel and mixed well. The DNA-gel mixture
was then run through Qiagen quick spin columns 700µL at a time, and finally washed with
PE Buffer (provided in the QIAquick Gel Extraction Kit Cat#28704). The DNA was eluted
from the column with 50µL of ddH2O and was quantified via Thermo Scientific Nano Drop
2000. Calculation of the amplicon copy number in the eluted sample was performed
assuming that double stranded DNA is 660g/mol/bp.
Isolation of neutrophils from whole blood
18 to 20cc of whole blood in ACD was added to a 50mL conical vial containing 12mL of
6% Dextran. The solution was gently mixed and redistributed into four 15mL conical tubes
and allowed to sit at room temperature for 45 minutes. Once the red blood cells (RBCs)
have settled out of solution, the top yellow layer was removed and combined in a 50mL
conical tube. This fraction was centrifuged at 1,150rpm for 12 minutes using a low braking
speed at 4°C. The supernatant was discarded, and the pellet resuspended in 12mL of ice
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cold ddH2O for no more than 30 seconds in order to lyse the RBCs. 4mL of 0.6M KCl was
added to the solution in order to neutralize the osmotic shock. The volume was increased
to 50mL using ice cold 1x PBS and centrifuged at 1,300rpm for 6 minutes using a high
brake at 4°C. The RBC lysis step was repeated with ddH2O and KCl until no more RBCs
were visible in the pellet after centrifugation. The supernatant was discarded and the pellet
resuspended in 2.5mL of 1x PBS and kept chilled. 3mL of Ficoll Histopaque 1119 (Sigma
Aldrich Cat# 11191-100mL) was added to a separate sterile 15mL conical tube. The
resuspended pellet was carefully layered on top of the Ficoll while tilting the conical tube
45°. The mixture was centrifuged at 1,500rpm using a low brake for 30 minutes at 4°C.
The supernatant was discarded leaving the neutrophil pellet. The pellet was resuspended
in 1mL of 1x PBS in order to perform a cell count. The neutrophil pellet was lysed at a
concentration of 5.0 x 106 cells/mL in Buffer containing: 50mM Tris Base; 500mM NaCl;
4mM MgCl2; 1% Triton X-100; 1mM PMSF protease inhibitor.
Immunoblotting of Neutrophil Protein Lysates
Protein lysates were treated with PNGase F (New England Biolabs Cat# P0705S)
according to the manufacturer’s protocol. Protein concentrations were determined with the
Pierce™ BCA Protein Assay Kit (Cat# 23225) and 20µg of total protein was added to a
10% polyacrylamide gel and transferred to nitrocellulose membrane. Antibody dilutions
were as follows: LPP3 (1:200) and beta-actin (1:5,000). As an alternative loading control,
after the protein transfer, gels were placed in 0.1% coomassie stain overnight and
destained for 2 hours in 10% acetic acid, 50% methanol and 405 ddH2O. Gels and
membranes were imaged with a Li-Cor Odyssey Scanner.
Statistical Analysis
All data are expressed as mean ± SEM unless otherwise noted. Statistical analysis was
performed using an unpaired, two-tailed Student t-test unless otherwise noted. P-value <
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0.05 is regarded as significant. ANOVA was used when multiple comparisons were made.
Statistical analysis was performed using GraphPad Prism 7.

Results
Neutrophils express detectable levels of LPP3
We evaluated LPP3 expression in separate blood fractions and observed that neutrophils
(PMNs), but not other leukocytes, platelets or red blood cells, express detectable levels of
LPP3 by Western blot (Figure 3.2a). We also determined LPP3-specific phosphatase
activity is significantly higher in the PMN fractions compared to the other blood cells by
immunoprecipating LPP3, incubating the lysates with LPA and measuring the production
of monoacylglyercol via HPLC MS/MS (Figure 3.2b).
Similar observations are discussed in Chapter 2 when we looked at LPP3 expression in
human macrophages treated with vehicle or oxLDL (50µg/mL). Naïve macrophages
exposed to vehicle show nearly undetectable levels of LPP3 but treatment with oxLDL for
48 hours resulted in significant increases in expression (Figure 2.1a).
Rs17114036 proxySNP rs9970807 associates with lower PPAP2B expression in
leukocytes
A meta-analysis was published in 2011 that associated a SNP in PPAP2B, rs17114036,
with CAD. The CARDIoGRAM Consortium reported that the SNP rs17114036, located
within the final intron of the gene PPAP2B, was highly predictive of CAD (odds ratio 1.17;
P = 3.81 X 10-19). Based on those observations, we interrogated publically available data
sets using information obtained with software tools and data available online at
http://www.sanger.ac.uk/resources/software/genevar/

(details

provided

in

45

and

http://compute1.lsrc.duke.edu/softwares/SNPExpress/1_database.php (details provided
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in 46. Using rs9970807 as a proxy SNP (r2=0.901), we found a significantly lower
expression of most of the PPAP2B exons in mRNA isolated from peripheral blood
monocytes from individuals with the risk-associated allele (Table 2.1). In contrast, the
proxySNP did not associated with altered expression of PRKAA2, encoding the α2
catalytic sub-unit of AMP-activated protein kinase, which is the closest known structural
gene to rs17114036 located ~66,000bp from PPAP2B on the opposite strand of the
chromosome in either blood cells (which express PRKAA2 at low levels), or in skin and
adipose tissue where the gene is expressed more strongly. We also queried the
SNPExpress database for an allele-associated change in PCKS9 expression but no
significant changes were observed in any of the probed exons (Table 2.2). These
observations support our hypothesis that the major allele of rs9970807, (and therefore,
the risk allele in rs17114036), is associated with decreased expression of LPP3.
Individuals homozygous for rs17114036 risk allele show no change in neutrophilspecific LPP3
Data from online microarray databases demonstrate a significantly lower level of PPAP2B
expression in PBMCs associated with rs9970807, a proxySNP in linkage disequilibrium
with rs17114036. Given the high expression of LPP3 in neutrophils we investigated
whether individuals homozygous for the CAD-associated risk allele for rs17114036
express lower levels of LPP3 compared to heterozygote PMNs. 75 volunteers were
enrolled in the study. The PMN fraction was isolated as described in materials and
methods and LPP3 expression was determined with Western blot. We were unable to
detect a difference in LPP3 expression between genotypes with Western blotting (Figure
2.3). We observed a risk allele frequency of 0.90 and a protective allele frequency of 0.10
in this cohort.
Peripheral blood from patients with acute myocardial infarction does not have
upregulated PPAP2B expression
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PMNs exhibit high levels of LPP3 expression, but no difference was observed in the tissue
from volunteers homozygous for the rs17114036 risk allele and those who were
heterozygous. The microarray database SNPExpress shows risk allele-associated
decreases in PPAP2B in PBMCs, which include monocytes but not the poly-nucleated
neutrophils suggesting that the SNP-effect may be cell-specific. As mentioned previously,
in a collaborative study with Reschen et al., our lab observed an upregulation of PPAP2B
during the conversion of primary human macrophages to foam cells (Figure 2.1) that
coincides with a CAD-associated risk allele-dependent variation of PPAP2B expression,
the details of which were described in greater detail in Chapter 2, further supporting the
concept of a tissue-specific SNP-effect. Mounting genomic data supports a role for SNPmediated PPAP2B expression in increasing an individual’s risk of developing CAD and
recent collaborative data suggests monocytes can upregulate LPP3 in response to a
characteristic CAD process; therefore, we hypothesized that PPAP2B expression would
be upregulated in the blood of patients with acute MI, another critical event in CAD.
To explore this possibility, we performed a pilot study that enrolled 29 subjects who either
healthy (n=10), had SIHD (n=10) or presented with acute MI (n=9). Blood was collected
within 24 hours of presented with MI. The demographics and clinical information on
subjects are presented in Table 2.3. We were unable to detect LPP3 reliably by Western
blotting and so we employed gene expression analysis. There was no observable
difference in PPAP2B expression between the three cohorts determined by qRT-PCR
using the ΔΔCT method (Figure 2.5).

To eliminate the possibility that comparative

quantification overlooked any differences in expression we generated a copy number
standard targeting PPAP2B. qRT-PCR using a standard curve revealed no differences in
absolute PPAP2B copy number between the three cohorts (Figure 2.6). We observed a
risk allele frequency of 0.86 and a protective allele frequency of 0.14 in our pilot study.
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Discussion
There is a strong heritable component, aside from modifiable lifestyle behaviors, that
contributes to varying degrees of risk of developing CAD [4, 49, 50, 126, 134]. In 2011 a
meta-analysis confirmed 10 previously known risk-associated loci as well as identified 13
novel loci that contribute to an increased risk of disease [4]. Many of the aforementioned
loci, including rs17114036 in the final intron of PPAP2B, are not found in genes identified
as traditional risk factors. SNPs identified in GWAS analyses are not necessarily the
disease-causing loci and may simply represent a haplotype of many SNPs in linkage
disequilibrium; in fact, rs17114036 is in linkage disequilibrium with roughly 20 SNPs
(Figure 2.1). We interrogated publically available microarray databases [142, 148] and
identified rs9970807, a proxySNP to rs17114036 (r2=0.901), as having an alleledependent association with decreased PPAP2B expression in blood cells (Table 3.1) that
was not observed in PCSK9 (Table 3.2). We hypothesized that individuals homozygous
for the major allele (the risk allele) will exhibit decreased PPAP2B expression and thus
levels of its respective protein LPP3. We enrolled 75 volunteers in our study that were
genotyped for the SNP rs17114036 and evaluated levels of LPP3 in their PMNs with
Western blotting; however, we saw no differences in LPP3 based on the individuals’
genotypes (Figure 3.3). Recent evidence leads us to believe that the SNP-effect on
PPAP2B expression is tissue-dependent and could be observed in models evaluating
CAD processes such as foam cell formation (Figure 2.1) [135]. A hallmark event in CAD
is the rupture of the atherosclerotic plaque and subsequent MI; we therefore investigated
whether PPAP2B expression increases in peripheral blood cells from patients suffering
acute MI or SIHD relative to healthy controls. We enrolled 29 volunteers to our study and,
using RNA isolated from their peripheral blood, determined PPAP2B expression levels.
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We saw no differences in expression among the three cohorts enlisted in our study
suggesting that PPAP2B is not increased in circulating blood cells of patients with acute
MI or SIHD (Figure 3.4).
Data from SNPExpress are derived from peripheral blood mononuclear cells, which are
mononuclear blood cells such as lymphocytes and monocytes. We looked at LPP3
expression in blood cells and observed detectable levels exclusively in the neutrophil
(PMN) fraction and not other leukocytes, platelets or red blood cells (Figure 3.2). Because
of this observation we investigated LPP3 expression relative to the rs17114036 SNP
genotype in neutrophils. Lysates from neutrophils show marked variability in LPP3 bands
on a Western blot likely due to the proteins variable glycosylation coupled with the
interindividual variation in its expression. We treated lysates bound for a Western blot with
PNGase F, an amidase that cleaves between the innermost GlcNAc and asparagine
residues of high mannose, hybrid, and complex oligosaccharides from N-linked
glycoproteins, effectively removing glycans from LPP3 in order to generate one solid
quantifiable band at ≈31kDa. However, as mentioned previously, no detectable difference
was observed between lysates from homozygotes and heterozygotes (Figure 3.3)
suggesting that a SNP-mediated effect on LPP3 expression is not taking place in the PMN
fraction. A sample size determination analysis reveals that a group sample size n=28 for
both genotypes would be required to achieve 90% power to reject the null hypothesis of
equal means when the population mean difference is μ1 - μ2 = 0.6 - 0.7 = -0.1 with a
standard deviation for both groups of 0.2 and with a significance level (alpha) of 0.050
using a two-sided two-sample equal-variance t-test.

Acute MI is a defining moment in the progression of CAD as it is confers life threatening
risks to patients both in its acute phase through arrhythmia and sudden cardiac death as
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well as chronic sustained damage leading to left ventricular dysfunction and heart failure.
Generation of a thrombus in a coronary artery creates an ischemic environment in the
surrounding myocardium which immediately begins to necrose resulting in the release of
several measurable proteins into the circulation such as cardiac troponins T and I,
myoglobin and CK-MB [149]. Because the CAD-related process of foam cell formation
evoked upregulation of PPAP2B in monocytes we hypothesized that the gene’s
expression is also altered in another critical CAD event, MI. We investigated whether
peripheral blood from patients suffering from acute MI would demonstrate altered
expression of PPAP2B compared to patients with SIHD or healthy volunteers. Amy Chen
and I recruited volunteers for this study in accordance to the University of Kentucky IRB
approved protocol 11-0367 and analyzed PPAP2B expression in the three cohorts.
Neither comparative qRT-PCR nor absolute copy number qRT-PCR analysis revealed any
difference in the expression of PPAP2B suggesting that the gene’s expression is
unaffected following acute MI or in patients with SIHD (Figure 3.4). A sample size
determination analysis reveals that in a one-way ANOVA study, sample sizes of n=43 for
each group whose means are to be compared. The total sample of 129 subjects achieves
90% power to detect differences among the means versus the alternative of equal means
using an F test with a 0.0500 significance level. The size of the variation in the means is
represented by their standard deviation which is 10.50. The common standard deviation
within a group is assumed to be 32.94. Alternatively, the upregulation of LPP3 observed
in our collaborative efforts with Reschen et al. may be dependent on cholesterol-specific
effects within vascular tissue and not the blood cells in circulation. One potential drawback
from this particular study is that we looked at RNA from all peripheral blood cells whereas
monocyte-specific LPP3 expression was affected upon oxLDL treatment.
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CAD is the leading cause of death for both men and women worldwide and is
characterized by the narrowing of coronary arteries due to the accumulation of
atherosclerotic plaques within the vessel wall. CAD is considered a multi-factoral disease
involving uncontrolled inflammation, intravascular deposition of lipids, endothelial
dysfunction and dynamic vessel remodeling; all of which may lead to plaque rupture,
triggering thrombogenesis and MI. 660,000 Americans suffer from their first MI every year
and statistics say that 36% of men and 47% of women will die within 5 years of their initial
MI [150]. Predicting individuals’ risk of developing CAD is imperative to initiating
preventative care and lifestyle changes that may slow the progression of disease. The
Framingham Heart Study in 1948 was pivotal in identifying many of the classical risk
factors that are associated with CAD today. However, in spite of improvements in
modifiable risk factors, CAD remains the primary cause of death in the United States. CAD
has a strong heritable component and with the onset of genome-wide sequencing
technology, our capacity to predict genetically-associated CAD risk has tremendously
expanded. In 2016 the number of CAD-risk associated loci is up to 47, many of which are
not found in genes identified as traditional risk factors. Rs17114036 was identified as a
noncoding intronic SNP in PPAP2B that incurs an increase in CAD risk [4]. In the study
presented here we identified, based on publically available microarray data, a decrease in
PPAP2B expression in PBMCs associated with the risk allele of rs9970807, a proxySNP
in linkage disequilibrium with rs17114036; additionally, we investigated whether a SNPdependent variation in LPP3 expression was detectable in human PMNs; as well as,
whether peripheral blood from patients with acute MI exhibit altered PPAP2B expression.
Although no differences were observed in neutrophil-specific LPP3 levels or peripheral
blood PPAP2B following acute MI, we can rule out the possibility that rs17114036 plays a
major role in the basal expression of LPP3 in PMNs and that acute MI or SCD contribute
to changes in PPAP2B expression.

88

Acknowledgements
This investigation was a collaborative effort from members in our lab including Amy Chen
and Dr. Travis Sexton and myself and was integral in earning my Certificate in Clinical and
Translational Research. Amy and I performed the volunteer enrollment: specifically, Amy
enrolled all patients whose RNA was analyzed in Figure 2.3 and compiled the data used
to generate Table 2.2. Dr. Travis Sexton’s expertise in molecular biology and genetics
designed the oligos used to generate a copy number standard for PPAP2B used to
generate data for Figure 2.3.b Amy and I shared the task of enrolling and drawing blood
from the volunteers whose samples were important in generating Figure 2.2. Under the
guidance of my mentor Dr. Susan Smyth I performed the SNPExpress analysis of
rs9970807 used to generate Table 2.1. I was able to generate Figure 2.1 using SNP
Annotation and Proxy Search software provided by the Broad Institute and NCBI dbSNP
Short Genetic Variations GeneView. All genotyping, PMN isolations, Western blots and
qRT-PCR experiments were performed and interpreted by myself.

89

Table 3.1

rs9970807 Associates with Decreased Expression of PPAP2B Exons in PBMCs

Exon
Probe ID

p-Value

Beta
Coefficient

Transcript

0.5252

6.367

2414371
2414373
2414374
2414380
2414381
2414386

0.5693
0.007934
0.001704
1.60E-04
0.1643
2.44E-04

5.414
44.45
60.11
147.5
-35.21
81.23

2414387
2414398
2414418
2414419
2414420
2414421

0.001353
0.009513
9.09E-05
0.3132
0.2352
0.008217

68.95
188.4
77.81
37.46
-78.01
14.27

SNPExpress software is downloadable free of charge from Columbia University
Medical Center’s website and was developed by Dongliang Ge and David Goldstein
[142]. I performed a real-time association test for PPAP2B and the rs17114036
proxySNP rs9970807. Output data displays genotype-specific expression of PPAP2B
exon probes and their respective p-value and beta coefficient of regression. Exon probes
showing significant (P<0.05) genotype-specific variation in expression are highlighted in
yellow.
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Table 3.2

No observable association between rs9970807 and changes in expression of
PCSK9 Exons in PBMCs
Exon
Probe ID

p-Value

Beta
Coefficient

Transcript

0.9126

0.6958

2337420
2337421
2337422
2337423
2337425
2337426

0.458
0.6604
0.1879
0.09877
0.8072
0.1993
0.4829
0.7079
0.4198
0.1557
0.4395

-4.3
-4.861
-105.7
12.06
-3.246
-39.41
-54.96
2.321
-16.39
-23.16
6.272
2.69

2337429
2337431
2337432
2337433
2337434
2337435
241

0.8142

SNPExpress software is downloadable free of charge from Columbia University
Medical Center’s website and was developed by Dongliang Ge and David Goldstein
[142]. I performed a real-time association test for PCSK9 and the rs17114036 proxySNP
rs9970807. Output data displays genotype-specific expression of PCSK9 exon probes
and their respective p-value and beta coefficient of regression. None of the exon probes
displayed significant differences.
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Table 3.3

Volunteer Demographics and Clinical History

Total Volunteers
Genotype
A/A
A/G
G/G
Average Age
Demographics
Male
Female
BMI
Labs
Sodium
Creatinine

Healthy
10

SIHD
10

Acute MI
9

9
1
0

9
1
0

5
0
1

25.6

67.9

51.9

6 (60.0%)
4 (40.0%)
23.3 ± 3.8

9 (90.0%)
1 (10.0%)
29.6 ± 1.6

5 (55.5%)
4 (44.4%)
34.9 ± 8.2

-

140 ± 4.3
1.3 ± 0.5

139 ± 4.5
0.97 ± 0.3

4 (40.0%)
1 (10.0%)
0 (0.0%)
2 (20.0%)

8 (88.9%)
3 (33.3%)
6 (66.7%)
4 (44.4%)

Past Medical History
0 (0.0%)
Hypertension
1 (10.0%)
Obesity
0 (0.0%)
Tobacco
0 (0.0%)
Diabetes
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Figure 3.1

SNP Map of PPAP2B: ProxySNPs in linkage disequilibrium (r2 threshold > 0.8) with
rs17114036 were identified using SNP Annotation and Proxy Search software provided
by the Broad Institute. Relative SNP locations were determined using NCBI dbSNP
Short Genetic Variations GeneView.
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Figure 3.2

LPP3 is primarily expressed in the neutrophil (PMN) fraction in murine blood. (A)
Western blot analysis of LPP3 in lysates containing 40 mg total protein from the
indicated cells. M/L = monocyte / lymphocyte fraction. (B) LPA phosphatase activity was
measured in plasma and isolated blood cells. Results are presented as mean ± SD from
3 independent experiments. #P < 0.001 by Student’s t-test [133].
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Figure 3.3

Individuals homozygous for rs17114036 risk allele show no change in
neutrophil-specific LPP3. Peripheral blood PMNs were isolated from volunteers
and genotyped for rs17114036 as described in materials and methods. (Top)
Western blot analysis was performed using antibodies to LPP3 (1:200) and
(Bottom) quantified by normalizing to coomassie stained band at ≈75kDa. Data are
presented as mean ± SEM.
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Figure 3.4

Peripheral blood from patients with acute myocardial infarction does not
have upregulated PPAP2B expression. RNA was isolated from volunteer
peripheral blood as described in materials and methods. (A) Comparative qRTPCR showing relative expression of PPAP2B and (B) copy number qRT-PCR
based on a calibration curve generated from in house PPAP2B standards. Blue
circles represent samples from volunteers heterozygous for the risk allele and
orange circles are from samples from those homozygous to the protective allele.
All other circles are samples from volunteers homozygous for the risk allele. Data
are presented as mean ± SEM.
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Chapter 4: Lysophosphatidic Acid Redistributes to Atherogenic
Lipoprotein Fractions in Hyperlipidemic Mice

Introduction
LPA is a potent bioactive lysophospholipid that is found in nearly all eukaryotic tissues and
biological fluids including the plasma, ascites and bronchoalveolar lavage fluid. Our lab
and others have observed significant accumulation of LPA in both human and mouse
atherosclerotic plaques (Figure 4.1). LPA binds to any one of its six known GPCRs (LPA16) and elicits a multitude of responses in nearly every cell type studied [10, 11, 21, 24, 26,
84, 151-153]. LPA receptor signaling has been shown to modify vEC barrier function, SMC
dedifferentiation, migration and proliferation, and even increase foam cell formation in
macrophages in vitro. Thus LPA is poised to serve as an important regulator of vascular
tissue function. Plasma LPA increases in human disease-states from acute MI to ovarian
cancer. Feeding atherosusceptible Ldlr-/- mice chow diet supplemented with unsaturated
LPA increases the formation of atherosclerotic lesions compared to saturated LPA or
regular chow diet alone.
LPA is carried in plasma bound to proteins, largely albumin, in both human and mice.
Recent evidence suggests that LPA could associate with atherogenic LDL-C through the
conversion of its precursor LPC into LPA by the actions of the ENPP2 ATX. ATX is a
secreted lysophospholipase D found in both human and mouse plasma. Levels of ATX
correlate with circulating LPA levels, and genetic deletion or pharmacological inhibition of
ATX decreases circulating LPA, indicating that ATX is the primary determinant of plasma
LPA levels. LPC has been reported to be a major phospholipid component of LDL-C and
enzymatic cleavage of its choline head group by ATX generates LPA. The precursor
molecule to LPC is phosphatidylcholine (PC), which is found in abundance in dairy
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products as well as red meat. Feeding Western diet significantly increases unsaturated
LPA species 20:4 in the plasma of Ldlr-/- mice.
To investigate the dietary contribution to circulating LPA levels, C57BL/6, Apoe-/- and Ldlr/-

mice were fed either chow or Western diet for 3 weeks or 12 weeks. Western diet feeding

Apoe and Ldlr mice increased LPA in the plasma fractions containing low-density
atherogenic associated VLDL-C and LDL-C which was not observed in C57BL/6 mice.
Globally reducing LPP3, the enzyme responsible for hydrolyzing LPA, increases total
plasma LPA without altering LPA levels between lipoprotein and protein fractions in the
plasma.

Materials and Methods
Animals
All procedures conformed to the recommendations of Guide for the Care and Use of
Laboratory Animals (Department of Health, Education and Welfare publication number
NIH 78-23, 1996), and were approved by the Institutional Animal Care and Use
Committee. C57BL/6, Apoe-/- and Ldlr-/- mice were obtained from The Jackson Laboratory
(Bar Harbor, ME). MX-1Δ and fl/fl mice were generated as described in Chapter 3
Materials and Methods. Mice were housed in cages with HEPA-filtered air in rooms on 12hour light cycles, and fed Chow diet or RD Western Diet (Research Diets Cat#D12079B)
ad libitum for specified time points.
Isolating Plasma from Peripheral Blood in Mice
In the morning, peripheral whole blood was collected from mice via the retro-orbital vein
while mice were anesthetized with isoflurane. Whole blood was collected in a 1.5 mL
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Eppendorf tube containing 10 µL of 0.5 M EDTA and 50 µL CTAD (BD Vacutainer Ref#
367947). Blood samples were centrifuged at 12,000 rpm for 4 minutes and the plasma
fraction collected. Samples were placed on dry ice and subsequently stored at -80°C.

Measuring Total Cholesterol and Lipoprotein Cholesterol Distributions in Murine
Plasma
Total plasma cholesterol was measured using the Wako Diagnostics Cholesterol E Assay
(Wako Diagnostics Cat#439-175001) according to the manufacturer’s protocol. Plasma
lipoprotein cholesterol distributions were determined via fast-performance liquid
chromatography (FPLC). In short, 40µL of plasma from mice, diluted to a concentration of
1µg/µL of total plasma cholesterol, was injected on to a Superose6 FPLC column.
Cholesterol concentrations are determined by enzymatic colorimetric assay (Wako
Diagnostics) reading at 600nm as the elute flows off of the column.

Measuring Phospholipid Content in Murine Plasma
50 µL of plasma was added to 450 µL of 0.1 M HCl and underwent lipid extraction as
previously described in “Lipid extraction for analysis via mass spectroscopy”

FPLC Fractionation of Plasma for Determination of LPA
40µL of plasma from mice was injected into a Superose 6 HPLC column at a flow rate of
0.4mL/minute. Fractions were collected between 18 and 48 minutes and subjected to lipid
extraction as described below.
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Lipid extraction for analysis via mass spectroscopy
500µL of sample in 0.1M HCl were added to a 12mL glass lipid extraction tube containing
1mL of chloroform, 2mL of methanol, and 50µL of 1µM D7-sphingosine-1-phosphate as
an internal standard. Samples in the lipid extraction tubes were vortexed for 5 minutes,
and then placed on ice/kept at 4°C for at least 1 hour. 1mL of chloroform and 1.3mL of
0.1M HCl was added to the lipid extraction tubes and vortexed again for 5 minutes. The
samples were centrifuged at 3,000rcf for 10 minutes at room temperature, and the lower
aqueous phase was transferred to 4mL screw cap glass tube using a Pasteur pipette being
careful not to include the protein interphase. Samples were evaporated to dryness using
nitrogen in an N-evap under a fume hood. Once the samples were completely dried, 100µL
of methanol was added and the tubes were vortexed. Samples sat at room temperature
for 10 to 15 minutes and then transferred to an autosampler insert vial for analysis via
Agilent Zorbax C8 column and quantified by tandem mass spectrometry using an ABI
4000 QTrap hybrid linear ion trap triple quadrupole mass spectrometer. The mass
spectrometer was operated in selective reaction monitoring mode to measure lipid species
specific precursor product ion pairs with quantification accomplished by reference to
calibration curves generated using synthetic standards obtained from Avanti Polar Lipids
that were independently quantitated by phosphorous analysis as described previously.

Statistical Analysis
All data are expressed as mean ± SEM unless otherwise noted. Statistical analysis was
performed using an unpaired, two-tailed Student t-test unless otherwise noted. P-value <
0.05 is regarded as significant. Two way ANOVA was used when multiple comparisons
were made. Statistical analysis was performed using GraphPad Prism 7.
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Results
Cholesterol-rich diet increases circulating LPA in hyperlipidemic mouse models
We placed C57BL/6 wild-type, hyperlipidemic Apoe-/- and Ldlr-/- mice on normal chow and
Western diet for 3 weeks or 12 weeks. As expected, total plasma cholesterol were
elevated in the hyperlipidemic Apoe-/- and Ldlr-/- mice and increased upon Western diet
feeding for 3 weeks as well as 12 weeks (Figure 4.2a). Total plasma LPA was 75% higher
in the hyperlipidemic mice on chow diet and nearly 4-fold in Apoe-/- and Ldlr-/- on Western
diet for 3 weeks compared to levels in C57BL6 wild-type control on the same diet. (Figure
4.2b).
Hyperlipidemia increases unsaturated LPA levels in fractions containing
atherogenic lipoproteins in mice
LPA is primarily bound to plasma proteins in mice and humans; however, its precursor
LPC is a major phospholipid component of lipoproteins in humans. We investigated
whether hyperlipidemia changed the plasma LPA content in the atherogenic-lipoproteins.
For the analysis, plasma was separated by size exclusion chromatography and fractions
were subjected to LC MS/MS to measure LPA content.
C57BL/6 and Apoe-/- mice show LPA content localized primarily in the late fractions 16 to
21 containing HDL-C or plasma proteins whereas Ldlr-/- plasma show small increases in
fractions 1 to 10 that typically contain LDL-C (Figure 4.3 top). Western diet feeding for 3
weeks results in a dramatic increase in LPA in plasma fractions containing LDL-C in
hyperlipidemic mice. The wild-type control plasma looks similar to its chow fed
counterpart. Apoe-/- and Ldlr-/- mouse plasma shows substantial increases in fractions 1
through 6 that contain the atherogenic VLDL-C and LDL-C (Figure 4.3 bottom). C57BL/6
mice fed Western diet for 12 weeks show only modest increases in total cholesterol
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compared to 3 weeks or chow diet (Figure 4.2a). Prolonged feeding of Western diet alters
the LPA content in the lower density fractions in C57BL/6 mice; specifically the
unsaturated LPA content (percent of total). The majority of LPA content in chow fed wildtype mice is found in fractions 18 to 23 but increases in fractions 13 to 18 in mice fed
Western diet for 12 weeks (Figure 4.4).
Although LPA increases in fractions typically containing atherogenic-associated LDL-C in
hyperlipidemic mice, we cannot say with certainty that these fractions contain their
predicted LDL-C. Using size exclusion chromatography we simultaneously measured
plasma total cholesterol (mg/dL) as it eluted out of the column with an enzymatic
colorimetric assay as described in the Materials and Methods. Overlaying the cholesterol
distribution curve with the corresponding time in which each fraction is collected, we see
a tight overlap of LPA content with the total plasma cholesterol (Figure 4.5).
Global reduction of LPP3 does not alter plasma-LPA localization
LPP3 is a member of the LPP family of phosphatases who dephosphorylate LPA and limit
LPA receptor signaling. Our lab has previously shown that endothelial cell-specific deletion
of LPP3 results in a significant LPA-dependent decrease in vEC barrier function [22]
suggesting that the phosphatase plays a role in limiting LPA-induced vEC permeability. In
Chapter 3 I reported that the global LPP3-deficient MX-1Δ mice fed Western diet have
significantly increased lesion formation compared to fl/fl control mice (Figure 211a) that
coincides with increased circulating plasma LPA (Figure 2.10d) as well as increased LPA
in the proximal aorta (Figure 2.11b). We hypothesized that global reductions in LPP3
would lead to increased LPA content in the plasma fractions containing LDL-C compared
to fl/fl controls.
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Plasma from MX-1Δ and fl/fl mice was separated by size exclusion chromatography as
previously described and LPA content was determined with LC MS/MS. As expected we
observed increased total LPA content in plasma from MX-1Δ mice compared to fl/fl
controls (Figure 4.6); however, we were unable to detect any differences in the LPA
content from fractions containing LDL-C (Figure 4.7).

Discussion
LPA accumulates in human atheroma and hyperlipidemic Apoe and Ldlr mice fed Western
diet for weeks (Figure 4.1a). Interestingly, we observed dramatic increases in unsaturated
LPA species 18:1, 20:3, 20:4, 20:5, 22:5 and 22:6 in hyperlipidemic mouse atheroma
compared to saturated 16:0 and 18:0 species which were still increased but not to the
same extent (Figure 4.1b). ApoE-/- and Ldlr-/- mice fed chow diet have increased
cholesterol and total LPA compared to C57BL/6 controls fed the same diet (Figure 4.2).
Feeding Western diet for 3 weeks dramatically increases plasma cholesterol and total LPA
content in hyperlipidemic mice compared to wild-type controls (Figure 4.2b). Plasma LPA
from wild-type mice and Apoe-/- fed chow diet was observed in fractions containing HDLC and plasma proteins (Figure 4.3). Ldlr-/- mice fed chow diet have LPA content in fractions
containing HDL-C and plasma proteins, but also have slight increases fractions 1 through
10 containing LDL-C (Figure 4.3). Feeding Western diet for 3 weeks increases plasma
LPA content in fractions 1 through 10 in hyperlipidemic mice but not wild-type mice
suggesting increased LPA association with LDL-C. Interestingly, the unsaturated LPA
content is markedly increased in hyperlipidemic plasma fractions that contain LDL-C
compared to saturated LPA. While wild-type mice show only modestly increased total
plasma LPA content and no increase in LPA content in fractions containing LDL-C (Figure
4.3), feeding C57BL/6 mice Western diet for 12 weeks increases the proportion of plasma
LPA content in lower density fractions 13 to 18 whereas LPA content is primarily found in
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fractions 18 to 23 in chow fed mice. Additionally, we demonstrated that the plasma
cholesterol distribution overlaps with the collected fractions used for determined LPA and
increased LPA content in fractions 1 through 10 of hyperlipidemic mice correlates with
sharp increases in plasma cholesterol (Figure 4.5). Finally, we show that while global
reductions in LPP3 increases total plasma LPA it does not increase LPA content in
fractions containing LDL-C relative to control mice.
The Increased accumulation of unsaturated LPA in fractions containing LDL-C in
hyperlipidemic mice (Figure 4.3) is interesting in the context of atherosclerosis. Navab et
al., demonstrates that intestinally-derived unsaturated, but not saturated, LPA increases
atherosclerotic lesion formation in Ldlr-/- mice [123]. Navab et al.’s observations are also
supported in a study published by Zhou et al., where i.v. administration of 20:4 unsaturated
LPA, but not 18:0 saturated LPA, increased atherosclerotic lesion formation in Ldlr-/- mice,
which could be inhibited with LPA1/3 antagonist Ki16425 [14]. In the latter study,
unsaturated LPA administration coincided with increased CD68 positive staining in
atheromas and upregulation of vEC adhesion molecule CXCL1. Wild-type mice fed
Western diet for 12 weeks resulted in an increase in LPA content, specifically the
unsaturated species, into the lower density plasma fractions 13 to 18 suggesting that
LPA’s association with fractions containing LDL-C in the plasma can be affected by diet
and not solely through hyperlipidemia. In either case, it is feasible that a cholesterolenriched diet leads to increases in unsaturated LPA accumulation in circulating LDL-C
that is deposited within the vessel wall and propagates LPA receptor signaling to drive
multi-tissue dysfunction and lesion formation.
Limitations of this study heed further investigation and lacks some important physiological
read-outs. For instance total triglyceride measurements would be helpful in the
interpretation of Figure 4.4 in which C57BL6 mice were fed Western diet for 12 weeks.
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The LPA distribution shifts to the lower density fractions which cannot be attributed to an
increase in cholesterol. Perhaps an increase in circulating triglycerides could account for
differences between chow and Western diet fed LPA distributions. Likewise I did not
perform an analysis of the total LPA in the mice represented in Figure 4.4 that would be
useful in determining there was change in absolute LPA between chow diet and prolonged
Western diet administration. Lastly, while we are able to demonstrate that the cholesterol
distribution in plasma correlates with the fractions we are collecting and associating with
LPA we still have not shown physical LPA-LDL-C binding in these fractions. To address
this point Dr. Fred Onono has performed immunoprecipitation of ApoB from human
plasma and determined LPA content using LC MS/MS. He observed that 10 to 65% of
total circulating LPA is physically associated with the LDL-C protein ApoB depending on
whether the individual was in a fed or fasted state (Data not shown).
To summarize, Western diet fed hyperlipidemic mice demonstrate dramatic increases in
LPA content in the LDL-C plasma fractions relative to their chow fed counterparts and
specifically in the unsaturated species suggesting that LPA in hyperlipidemic models may
be bound to LDL-C and could elicit a multitude of effects on the vasculature via LPA
receptor signaling. Additionally, LDL-C may in fact be a source of not just LPC, but also
LPA in atherosclerotic lesions that would be supported by our observation of increased
unsaturated LPA species in murine lesions. Aside from models of hyperlipidemia,
unsaturated LPA content in the LDL-C plasma fractions are affected by prolonged
administration of cholesterol-enriched diet which may be of relevance considering recent
investigations by Zhou et al., and Navab et al. demonstrating a role for both circulatory
and intestinally-derived unsaturated LPA in increasing atherosclerotic lesion formation in
mice.
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Figure 4.1

LPA accumulates in human and murine atheroma. Human atheroma and mouse
proximal aortas were subjected to lipid extraction to determine LPA concentrations. LPA
presented as pmol and normalized to 10 nmol of phosphate calculated using a
phosphate binding protein assay (abcam). Human atheroma and chow diet fed mouse
samples are represented in blue while Western diet fed mouse samples are represented
in red. Data are presented as mean ± SD. *P<0.05
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Figure 4.2

Total plasma LPA increases in hyperlipidemic mice fed Western diet. C57BL/6
(blue), Apoe-/- (red), and Ldlr-/- (green) mice were fed normal chow or Western diet for 3
or 12 weeks. (A) Total plasma cholesterol (mg/dL) from three cohorts (n=5 for each
genotype). (B) Total plasma LPA (µmols) determined with HPLC MS/MS from mice fed
normal chow and Western diet for 3 weeks (n=5 for each genotype). Data are presented
as mean ± SEM.
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Figure 4.3

Western diet induces the redistribution of LPA in plasma of hyperlipidemic mice.
C57BL/6, Apoe-/-, and Ldlr-/- mice were fed (Top) normal chow or (Bottom) Western diet
for 3 weeks. Plasma was injected into a FPLC column and fractionated as described in
methods and materials. Plasma LPA (pmol/Fraction) is presented as total LPA (yellow),
saturated LPA (red) and unsaturated LPA (green).
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Figure 4.4

Prolonged Western diet feeding shifts plasma LPA to lower density fractions in
wild-type mice. C57BL/6 mice were fed (Top) normal chow (n=3) or (Bottom) Western
diet (n=3) for 12 weeks. Plasma was injected into a FPLC column and fractionated as
described in Methods and Materials. Plasma LPA (% of total) is represented as total LPA
(yellow), saturated LPA (red) and unsaturated LPA (green). Data are presented as mean
± SEM.
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Figure 4.5

Plasma LPA fractions correlate with total cholesterol curves. Representative image
of LPA (pmol/fraction) and plasma cholesterol (mg/dL) from MX-1Δ mouse plasma.
Plasma was injected into a FPLC column and fractionated as described in Methods and
Materials. Cholesterol concentration was determined using enzymatic colorimetric assay
reading at 600nm as the elute flows off of the column. LPA fractions are given at their
respective time of collection during the fractionation process.
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Figure 4.6

Global reduction of LPP3 does not alter plasma LPA distribution. (Top) fl/fl (n=2)
and (Bottom) MX-1Δ (n=5) mice were fed Western diet for 12 weeks. Plasma was
injected into a FPLC column and fractionated as described in methods and materials.
Plasma LPA (pmol/Fraction) is represented as total LPA (yellow), saturated LPA (red)
and unsaturated LPA (green). Data are presented as mean ± SEM.
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Figure 4.7

LPA species subtype does not change with global reductions in LPP3. ) MX-1Δ
(n=5) mice were fed Western diet for 12 weeks. Plasma was injected into a FPLC
column and fractionated as described in methods and materials. LPA (pmol/Fraction)
from MX-1Δ (red) and fl/fl (black) mice was compared based on species: (Top) Total
LPA, (Middle) saturated LPA and (Bottom) unsaturated LPA. Data are presented as
mean ± SEM.
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Chapter 5: Discussion
So far this dissertation has provided a detailed discussion on mechanisms of
atherosclerosis and proposes a role for the ATX-LPA-LPP3 signaling axis in the
development and regulation of disease. I provide evidence that LPP3 expression limits
lesion formation in murine models of atherosclerosis and that CAD-associated risk loci
within PPAP2B decrease its expression in a cis-manner. Finally, I demonstrate LPA
content increases in plasma fractions containing LDL-C in hyperlipidemic mice on a
cholesterol-enriched diet. In this chapter I will review data presented in this dissertation
and discuss the overarching potential for CAD-associated risk alleles to limit PPAP2B
expression in atherosclerosis driving local increases in LPA signaling that may be
exacerbated based on a diet.
CAD-associated risk loci decrease PPAP2B expression in a cis-manner
In Chapter 2 I present data that our lab generated in collaboration with Reschen et al. that
demonstrates upregulation of LPP3 protein in human foam cells that is absent in naïve
vehicle treated macrophages (Figure 2.1). These data support observations from the
Oxford group that the CAD-associated SNP rs72664324 diminishes the ability of
macrophages to upregulate PPAP2B expression upon exposure to oxLDL by breaking a
C/ETP binding motif. In fact, when macrophages were treated with oxLDL Reschen et al.
observed open chromatin site remodeling in the region of PPAP2B that harbors
rs72664324 using FAIRE-seq. rs72664324 is a proxySNP in linkage disequilibrium with
rs17114036 and is in a C/EBP CCAAT binding motif. Presence of the protective allele
(A) facilitates the transcription factor binding and subsequent expression of PPAP2B;
however, presence of the risk allele (G) disrupts this motif resulting in the diminished
upregulation of PPAP2B as described above. Their study reveals a mechanism for

114

PPAP2B upregulation in a key cellular process in atherosclerosis that is limited by a cisacting CAD-associated risk allele in rs72664324.
I present additional evidence in Chapter 3 that CAD-associated risk alleles are acting in a
cis-manner on PPAP2B. I searched a publically available database for microarray data
looking at SNP-mediated effects on gene expression. Table 3.1 contains PPAP2B exon
probes that displayed significant decreases in expression associated with the risk allele of
rs9970807, another proxySNP in linkage disequilibrium with rs17114036. The CADassociated risk loci are found on chromosome 1; interestingly, PCSK9 is also found on
chromosome 1 and is considered a master regulator of cholesterol and, as such, is highly
implicated in the development of CAD. To rule out that risk loci in PPAP2B are not
conferring increased risk of disease by modifying PCSK9 transcript levels in a transmanner, I searched the database for the same SNP-mediated effects on PCSK9
expression. Table 3.2 contains PCSK9 exon probes; however, unlike PPAP2B, the
PCKS9 exon probes expression were unaffected by the presence of rs9970807. This
suggests that CAD-associated risk alleles are, in relation to PCSK9, not acting in a transmanner but do regulate PPAP2B expression in cis.
It is worth mentioning that a study published by Erbilgin et al. also demonstrates risk alleledependent decreases in PPAP2B expression in HAECs. Taking these data together, CADassociated risk alleles identified within PPAP2B are capable of regulating PPAP2B’s
expression in a cis-manner and demonstrate no trans-mediated effects on PCSK9
expression.
Ppap2b expression limits lesion formation in murine models of atherosclerosis
In Chapter 2 I provide evidence that LPP3 expression increases in murine models of
atherosclerosis that is not observed in healthy vasculature (Figure 2.2 through 2.7). We
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also demonstrated the same C/ETP binding to rs72664324 in a macrophage mouse line
RAW264.7 that was observed in human macrophages by Reschen et al. These data
suggest that atherosclerotic vessels upregulate LPP3 in response to disease.
We next generated a murine model of atherosclerosis with global leukocyte-specific and
SMC-specific reductions in LPP3. Our inducible global Ppap2b knockout mice had a 30%
increase in atherosclerotic lesion formation compared to fl/fl control mice (Figure 2.11a)
despite no differences in plasma cholesterol (Figure 2.10a). Increased atherosclerosis
coincided with increased plasma LPA (Figure 2.10d) as well as an accumulation of LPA
within the proximal aortas of MX-1 mice compared to their controls (Figure 2.11b).
Interestingly, increased Cd68 expression was observed in the proximal aortas determined
by qRT-PCR (Figure 2.11c) that is supported by increased positive CD68 staining in aortic
root lesions (Figure 2.11d). ICAM-1 staining was also dramatically higher in MX-1 aortic
root lesions compared to fl/fl mice suggesting an increase in the vEC adhesion molecule
(Figure 2.12). We detected no differences in lesion formation in the leukocyte-specific
deletion of Ppap2b (Figure 2.14); however BMDMs from LysM- mice have increased
proinflammatory Il1b and Il12b expression compared to fl/fl control cells (Figure 2.13b).
This observation suggests that while leukocyte-derived LPP3 may be insufficient to confer
protection against lesion formation, it is important in limiting inflammation. Finally, we
observed increased lesion formation in mice deficient in SMC-derived LPP3 (Figure16a)
despite, again, no differences in plasma cholesterol (Figure 2.15b). Proximal aortas from
mice deficient in LPP3 from SMCs show significantly higher LPA content (Figure 2.16b)
as well as Il6 expression (Figure 2.16c) and their aortic root lesions have increased CD68
expression (Figure 2.16d) similar to what was observed in the global LPP3 knockouts.
Chapter 2 provides evidence that SMCs also upregulate PPAP2B in response to
cholesterol loading (Figure 2.17b). This is an interesting observation considering data
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generated in our collaboration with Reschen et al., that macrophages upregulate LPP3 in
response to oxLDL-induced foam cell formation. Recent evidence proposes that SMCs
make up nearly 50% of foam cells present in atherosclerotic plaques, and therefore their
PPAP2Bs role in their phenotypic conversion may be an interesting cellular mechanism to
investigate.
Global reductions in LPP3 in our murine model resulted in increased expression of Cd68
in proximal aortas. CD68 positive staining in the aortic root lesions of MX-1 and SM22-
mice were also increased compared to their respective controls. This observation can be
explained by the simple fact that a larger lesion size suggests more foam cells.
Alternatively, as is suggested by the increased ICAM-1 staining in MX-1 lesions, there
could be an increased propensity for leukocyte infiltration into the vessel wall when LPP3
is absent. This latter hypothesis would have to be investigated with cell sorting using
FACS. Liping Yang from our lab has preliminary data that aorta from SM22- mice do
have increased CD68 positive cells compared to fl/fl controls but more experiments should
be carried out to confirm this observation. Our lab has previously shown that mice with
targeted inactivation of LPP3 in their endothelial cells have decreased endothelial barrier
function [22] and increased vEC permeability increases leukocyte infiltration into vessels
and increases lesion formation [154]. In our model of LPP3-dependent vascular barrier
function, the increased endothelial permeability in LPP3-deficient mice could be
attenuated with an ATX inhibitor or a LPA receptor pan antagonist suggesting that LPA
signaling is regulating the observed phenotype. LPA signaling has been shown to regulate
vEC barrier function before and could provide a mechanism for increased atherosclerotic
lesion formation in these mice.
Myeloid cell-specific deletion of LPP3 did not increase the development of atherosclerotic
lesions in mice suggesting that the phosphatase in macrophages in not important in
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protecting mice from disease (Figure 2.14). However, another way to interpret the data is
that the expression of LPP3 from macrophages is insufficient to confer protection
compared to the overall net expression of the phosphatase in lesion cells. As discussed
in “Chapter 1: Structure and Function of the LPPs”, LPP3 homologs are capable of
generating phospholipid gradients and thus affecting cells upwards of 33µm away [132].
It is feasible then that LPP3 expressed in SMCs (as well as other lesion cells not of myeloid
lineage) in the LysM- mice is capable of conferring protection to lesion development by
affecting cell types in a paracrine or non-autonomous manner, possibly through the
regulation of LPA or other phospholipid substrates. However, in both the global and the
SMC-specific models of LPP3 deficiency, enough of the phosphatase has been knocked
out to abrogate the non-autonomous manner of protection.
LPA content increases in plasma fractions containing LDL-C in hyperlipidemic
mice
I present preliminary evidence in Chapter 4 that LPA content increases in plasma fractions
containing LDL-C in hyperlipidemic mice. Previously, LPA was found primarily bound to
plasma proteins; however its precursor molecule, LPC, is known to be a major
phospholipid component of plasma lipoproteins [155]. Interestingly, unsaturated LPA
content demonstrates large increases in the plasma fractions containing LDL-C from
Apoe-/- and Ldlr-/- mice fed Western diet for 3 weeks (Figure 4.3). Unsaturated LPA has
been shown to increase atherosclerotic lesion formation in several investigations [14, 123]
and its increase in LDL-C would propose a mechanism in which atherogenic LPA species
are introduced into the vessel wall with LDL-C deposition.

Overview
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In this dissertation I present a model for LPP3 in limiting the lesion formation in murine
models of atherosclerosis which supports our hypothesis that CAD-associated risk loci in
PPAP2B are acting in a cis-mediated fashion to diminish LPP3 expression in individual’s
homozygous for the risk alleles (Figure 5.1). LPP3 plays a protective role in the
development and progression of atherosclerosis by limiting LPA signaling in the vessel
wall, resulting from deposition of LDL-C carrying atherogenic unsaturated LPA, and
individuals who are unable to upregulate PPAP2B in response to atherosclerotic stimuli
are at increased risk of CAD.
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Figure 5.1
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Figure 5.1 (Caption)

Proposed model for ATX –LPA–LPP3 nexus in atherosclerosis and it complications.
Top, At least a portion of circulating ATX may derive from adipose tissue. Middle, ATX derived LPA has potent effects on several blood and vascular cells that could potentially
contribute to biological events that underlie atherosclerosis. In addition, atherosclerotic
plaque is enriched in LPA. Bottom, Circulating and secreted ATX may interact with
integrins and through non–integrin-mediated mechanisms to generate a local gradient of
LPA. ATX contains a catalytic phosphodiesterase (PDE) domain, a nuclease like (NUC)
domain and integrin binding somatomedin B like (SMB) domains. LPA signaling through
G-protein–couple receptors LPA1–6 and possible receptor for advanced glycan end
products (RAGE) may be terminated by enzymatic dephosphorylation catalyzed by
LPPs. Whether ATX promotes and LPP3 suppresses atherosclerosis remains to be
established. Illustration by Matt Hazzard, University of Kentucky, Information
Technology. LDL indicates low-density lipoprotein; LPC, lysophophosphatidyl choline;
and lyso-PLD, lysophospholipase D [156].
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